



ISPOR 20th Annual European Congress

4-8 NOVEMBER 2017

SCOTTISH EVENT CAMPUS (SEC)

GLASGOW, SCOTLAND



Photo credit: University of Glasgow

The Evolution of Value in Health Care

PROGRAM AND SCHEDULE OF EVENTS

 #ISPORGlasgow

WI-FI NETWORK: ISPORGLASGOW // PASSWORD: IQVIA2017


www.ispor.org



About ISPOR

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is the leading global scientific and educational organization for health economics and outcomes research (HEOR). ISPOR's mission is to promote HEOR excellence to improve decision making for health globally.

ISPOR Strategic Pillars



ISPOR Membership

ISPOR has a 20+ year legacy as an unbiased organization of more than 20,000 individual and chapter members. ISPOR promotes HEOR excellence through its:

- Scientific meetings and conferences
- MEDLINE®/PubMed-indexed journals
- Educational programs
- Roundtables, councils, and collaborative alliances
- Online tools
- Scientific and health policy groups
- Regional consortia, networks, and chapters
- Dialogue with payers and health care decision makers

Additional information on ISPOR and membership benefits can be found at www.ispor.org.



Table of Contents

Congress Program Committee	5
Event Sponsors	6
Plenary Sessions	7
Schedule of Events.	9
Saturday, 4 November	9
Sunday, 5 November	12
Monday, 6 November	15
Tuesday, 7 November	21
Wednesday, 8 November	27
Invitational Group Meetings	31
Poster Overview	34
Exhibit Program Overview	35
Exhibitor Listing	36
Exhibit/Poster Hall Floor Plan	37
Key Congress Information	39
Conference Rooms Floor Plan	40



We are advancing peri- and post-approval research.

38 Presentations at **ISPOR GLASGOW**

- 2** Short Courses
- 2** Workshops
- 3** Issue Panels
- 1** Forum
- 1** Podium
- 29** Posters

30+ Years of Experience

Epidemiology · Health Economics · Interventional Studies
Real-World Evidence · Patient-Centered Research · Evalytica®
Pragmatic / Adaptive Trials · Modeling and Meta Analysis
Market Access · Medical Writing

www.evidera.com

www.evalytica.com





Congress Program Committee

ISPOR thanks the Congress Program Committee for its contributions in developing the scientific community's leading HEOR program.

PROGRAM COMMITTEE CO-CHAIRS

Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK

Maarten IJzerman, PhD, University of Twente, Enschede, The Netherlands



Briggs



IJzerman

RESEARCH REVIEW COMMITTEE CO-CHAIRS

Margreet G. Franken, PhD, Erasmus University Rotterdam, Rotterdam, The Netherlands

Rok Hren, PhD, University of Ljubljana, Ljubljana, Slovenia

Andrea Manca, University of York, Heslington, York, UK

Ursula Rochau, MD, MSc, UMIT - University for Health Sciences, Medical Informatics and Technology, Tirol, Austria



Franken



Hren



Manca



Rochau

ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS

René Allard, PhD, Grünenthal GmbH, Aachen, Germany

Jan Geissler, Leukemia Patient Advocates Foundation, Patvocates, and European Patients' Academy (EUPATI), Munich, Germany

Camilla Palmhoj Nielsen, PhD, DEFACTUM, Aarhus N, Denmark



Allard



Geissler



Nielsen

WORKSHOP REVIEW COMMITTEE CO-CHAIRS

Raquel Aguiar-Ibáñez, MSc, MSD, Hoddesdon, UK

Martin Scott, MSc, Numerus Ltd., Tübingen, Germany

Allan Wailoo, PhD, University of Sheffield and NICE Decision Support Unit, Sheffield, UK



Aguiar-Ibáñez



Scott



Wailoo



Thank You to Our Event Sponsors

Platinum Level Sponsors



Gold Level Sponsors



Silver Level Sponsors



Bronze Level Sponsors



Supported by





Plenary Sessions Featured at ISPOR Glasgow

FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?

There now is a wide consensus that health care products and services should be priced in relation to the additional value they produce. While cost-effectiveness analysis explicitly assumes allocation of resources based on added societal value, practitioners and health care policy makers in European institutions now increasingly promote value-based health care (VBHC) as a more holistic, patient-centered understanding of value. Although VBHC seems well aligned with cost-effectiveness analysis, there are several fundamental differences. Where VBHC is embraced by health care practitioners and hospital administrators because of its focus on patient value over the entire care pathways instead of single interventions, it lacks an operational definition of value in relation to cost. Another difference is that outcomes in VBHC are disease-specific, which implies they cannot be used for societal resource allocation decisions. This plenary session will therefore introduce VBHC in more general terms from a clinical and hospital perspective, and then will specifically discuss the challenges and main differences with cost-effectiveness analysis from an industrial, health economics, and patient perspective.

Moderator: Maarten IJzerman, PhD, University of Twente, Enschede, The Netherlands
Speakers: Peter Naredi, University of Gothenburg and European CanCer Organization (ECCO), Brussels, Belgium; **Luke Slawomirski**, Organisation for Economic Co-operation and Development (OECD), Paris, France; **Bettina Ryll, MD, PhD**, Melanoma Patient Network Europe and European Society for Medical Oncology (ESMO), Uppsala, Sweden; **Jason Arora, MD, MPH**, Medtronic, Watford, UK



IJzerman



Naredi



Slawomirski



Ryll



Arora

SECOND PLENARY SESSION: APPRAISING THE APPRAISERS: WHAT IS THE FUTURE OF HEALTH TECHNOLOGY ASSESSMENT IN EUROPE?

Health technology assessment (HTA) processes vary across jurisdictions. Some countries are early adopters and include a formal economic evaluation (Canada, United Kingdom, Australia, Sweden, The Netherlands), others have a less arduous approach without formal QALY-type assessment (France, Spain, Italy), and still others prefer to reference HTAs performed elsewhere (Romania, Bulgaria). In addition, bodies such as EUnetHTA offer the potential to streamline processes by enabling information sharing and structured collaboration between jurisdictions. However, how cost-effective are the HTA processes? What is the value for money of the HTA activities? Is there a “perfect HTA process” that can serve as the benchmark for other countries to adopt or adapt? This plenary session will explore how HTA processes (or lack of HTA processes) might be compared and evaluated and the speakers will present different perspectives on evaluating the value of HTA processes.

Moderator: Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK
Speakers: Susan Guthrie, PhD, MSc, Rand Europe, Cambridge, UK; **Nicola Allen, PhD**, Precision for Value, London, UK; **Zoe Garrett, MPhil, MRes**, National Institute for Health and Care Excellence (NICE) and EUnetHTA, Manchester, UK



Briggs



Guthrie



Allen



Garrett

THIRD PLENARY SESSION: EVOLUTION OF VALUE: PERSPECTIVES FROM BOTH SIDES OF THE ATLANTIC

As the rate of medical innovation accelerates, competing demands from various stakeholders put unprecedented pressure on health systems to deliver high-value medical care. Most health systems claim to link coverage decisions to the value for money afforded by specific treatments, but their approaches to valuation differ. Many countries, such as the United Kingdom, have historically relied on traditional cost-effectiveness analysis using the cost-per-QALY metric to guide coverage decisions. Other countries like France and Germany never adopted the uncertain place of cost-utility analysis in the decision processes, relying instead on disease-specific metrics. The large majority of payers in the pluralistic US health care market deny explicit consideration of cost effectiveness in coverage decisions, and US law forbids its use as part of the Affordable Care Act. Instead, public and private payers in the United States increasingly push financial risk onto health care providers thereby, in a sense, decentralizing the assessment of value. Health economists from the United Kingdom, the United States, and France will provide reflective views on how valuation of medical technologies has changed across time and will discuss the methodological, societal, and political forces that shaped their evolution. The speakers will also consider what the future holds for valuation in health.

Moderator: Shelby D. Reed, PhD, RPh, Duke University, Durham, NC, USA
Speakers: Mandy Ryan, PhD, MSc, University of Aberdeen, Aberdeen, UK; **Charles E. Phelps, PhD**, University of Rochester, Gualala, CA, USA; **Jérôme Wittwer, PhD**, Bordeaux University, Bordeaux, France



Reed



Ryan



Phelps



Wittwer



A pharmaceutical company that helps you see what others don't

The Mundipharma global network of independent associated pharmaceutical companies successfully builds alliances to develop and market medicines.

We are looking for alliance partners developing therapies in pain, respiratory, oncology and biosimilars or new areas of exploration.

Contact us at: businessdevelopment@mundipharma.co.uk
www.mundipharma.com



Mundipharma International
Limited proud developers of the
BEACON framework

MIINT/UNAL - 17017b
August 2017



Congress Schedule of Events

SATURDAY, 4 NOVEMBER

7:00-18:00 **REGISTRATION HELP DESK HOURS Hall 5**

8:00-17:00 **SHORT COURSE FULL DAY (Separate Registration Required)**

Introduction to Health Economic/Pharmacoeconomic Evaluations Hall 2

Track: **Economic Methods**

Level: **Introductory** *This course is suitable for those with little or no experience with pharmacoeconomics.*

Faculty: **Lieven Annemans, PhD, MSc**, Ghent University - Brussels University, Ghent, Belgium

8:00-12:00 **SHORT COURSE MORNING SESSION (Separate Registration Required)**

Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources Lomond Auditorium (Loch Suite)

Track: **Observational Data Methods**

Level: **Introductory**

Faculty: **Linus Jönsson, PhD, MD, MSc**, H. Lundbeck A/S, Valby, Denmark; **Bradley C. Martin, PharmD, PhD, RPh**, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA

Introduction to Patient-Reported Outcomes Assessment Carron (Loch Suite)

Track: **Patient-Reported Outcomes Methods**

Level: **Introductory** *This is an entry level course which assumes only a passing familiarity with patient-reported outcomes.*

Faculty: **Kevin Weinfurt, PhD**, Duke Clinical Research Institute, Durham, NC, USA

Introduction to Modeling Boisdale (Loch Suite)

Track: **Modeling Methods**

Level: **Introductory** *This course is designed for those with some familiarity with modeling techniques.*

Faculty: **Uwe Siebert, MD, MPH, MSc, ScD**, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria

Development of Conceptual Models Leven+Morar+Ness (Seminar Suite)

Track: **Modeling Methods**

Level: **Introductory**

Faculty: **Neil Hawkins, PhD**, University of Glasgow, Glasgow, UK; **Mark S. Roberts, MD, MPP**, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA; **Elisabeth Fenwick, PhD, MSc**, ICON Health Economics and Epidemiology, Abingdon, UK; **Paul Tappenden, PhD, MSc**, University of Sheffield, Sheffield, UK; **Beth Woods, MSc**, University of York, Heslington, York, UK

Cost-Effectiveness Analysis Alongside Clinical Trials Alsh (Loch Suite)

Track: **Economic Methods**

Level: **Intermediate** *Familiarity with economic evaluations will be helpful.*

Faculty: **Richard J. Willke, PhD**, International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ, USA; **Lotte Steuten, PhD**, Hutchinson Institute for Cancer Outcomes Research (HICOR) and University of Washington, Seattle, WA, USA

Elements of Pharmaceutical / Biotech Pricing Hall 1

Track: **Use of Pharmacoeconomic / Economic / Outcomes Research Information**

Level: **Introductory** *This course is designed for those with limited experience in the area of pharmaceutical pricing and will cover topics within a global context.*

Faculty: **Jack M. Mycka**, Medical Marketing Economics LLC (MME), Montclair, NJ, USA; **Renato Dellamano, PhD**, MME Europe & ValueVector (Value Added Business Strategies), Milan, Italy



Conjoint Analysis – Theory & Methods *Dochart (Loch Suite)*

Track: **Patient Preference Methods**

Level: **Intermediate** *This course is designed for clinicians, policymakers, researchers, and patient advocates/researchers with some familiarity with conjoint analysis or other stated-preference methods.*

Faculty: **A. Brett Hauber, PhD**, RTI Health Solutions, Research Triangle Park, NC, USA; **John F. P. Bridges, PhD**, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

10:00-10:15 **COFFEE BREAK**

Coffee Break Sponsored by Sirius Market Access



12:00-13:00 **LUNCH** (*Attendees on their own*)

13:00-17:00 **SHORT COURSE AFTERNOON SESSION** (*Separate Registration Required*)

Introduction to Health Technology Assessment *Lomond Auditorium (Loch Suite)*

Track: **Use of Pharmacoeconomic / Economic / Outcomes Research Information**

Level: **Introductory** *This course is suitable for those with little or no experience with HTA.*

Faculty: **Uwe Siebert, MD, MPH, MSc, ScD**, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria

Meta-Analysis & Systematic Literature Review *Alsh (Loch Suite)*

Track: **Outcomes Research Methods**

Level: **Intermediate**

Prereq.: *Previous attendance at the ISPOR short course, "Statistical Methods for Pharmacoeconomics & Outcomes Research," or equivalent knowledge, is recommended.*

Faculty: **Olivia Wu, PhD**, University of Glasgow, Glasgow, UK; **Neil Hawkins, PhD**, University of Glasgow, Glasgow, UK

Statistical Methods for Pharmacoeconomics & Outcomes Research *Boisdale (Loch Suite)*

Track: **Economic Methods**

Level: **Introductory** *This course is intended for participants with little (or rusty!) statistical training.*

Faculty: **James Lewsey, PhD**, University of Glasgow, Glasgow, UK; **Gerd K. Rosenkranz, PhD**, Medical University of Vienna, Vienna, Austria

Use of Propensity Scores in Observational Studies of Treatment Effects *Leven+Morar+Ness (Seminar Suite)*

Track: **Observational Data Methods**

Level: **Intermediate** *This course is designed for those with little experience with this methodology but some knowledge of observational databases.*

Prereq.: *Previous attendance at the ISPOR short course, "Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources," or equivalent knowledge, is recommended.*

Faculty: **John D Seeger, PharmD, DrPH**, Optum, Waltham, MA, USA; **Jeremy A. Rassen, ScD**, Aetion, Inc., New York, NY, USA

Collecting Health-State Utility Estimates for Economic Models in Clinical Studies *Carron (Loch Suite)*

Track: **Patient Preference Methods**

Level: **Intermediate** *This course is for those with some experience with quality of life measures in health economic evaluation.*

Faculty: **Sorrel Wolowacz, PhD**, RTI Health Solutions, Manchester, UK; **Andrew Briggs, DPhil**, University of Glasgow, Glasgow, UK; **Andrew Lloyd, DPhil**, Acaster Lloyd Consulting Ltd., Oxford, UK; **Lynda Doward, MRes**, RTI Health Solutions, Manchester, UK

Pharmacoeconomic Modeling – Applications *Dochart (Loch Suite)*



Track: **Modeling Methods**

Level: **Intermediate**

Prereq.: *Previous attendance at, or familiarity with the topics discussed in the ISPOR short course, "Introduction to Modeling," is required.*

Faculty: **Shelby L. Corman, PharmD, MS, BCPS**, Pharmerit International, Bethesda, MD, USA; **Mark S. Roberts, MD, MPP**, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA



Indicates hands-on exercises requiring the use of your personal computer.



NEW! Introduction to Designing Authentic and Impactful Patient-Centered Outcomes Research *Hall 1*

Track: **Patient-Reported Outcomes Methods**

Level: **Introductory**

Faculty: **C. Daniel Mullins, PhD**, University of Maryland, School of Pharmacy, Baltimore, MD, USA; **Marvin Mack**, Center for Mind & Esteem Development, Baltimore, MD, USA; **Emil Chiauzzi, PhD**, PatientsLikeMe, Cambridge, MA, USA

15:00-15:15 **COFFEE BREAK**

17:30-18:30 **EDUCATIONAL SYMPOSIUM** (*Open to all attendees*) **Lomond Auditorium (Loch Suite)**

The Evolving Approach to Drug Value Assessment in Global Markets

Moderator: **David Rees, MBA**, Health Strategies Group, Yardley, PA, USA

Speaker: **Sanjay Shah, MBA**, Visionary Ventures, LLC., Morganville, NJ, USA, **Michael Schlander, MD, PhD, MBA**, InnoVal-HC, Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany, **Andreas Wildi, MD, Mlaw**, Walder Wyss Ltd., Zurich, Switzerland, **Jennifer Cain, MBA, MPH**, Roche, Basel, Switzerland, **Aris Angelis, MSc**, London School of Economics and Political Science, London, UK

(Sponsored by Health Strategies Group)



< advertisement >

Changing the practice of medicine

At Novartis, we harness the innovation power of science to address some of society's most challenging healthcare issues. We are passionate about discovering new ways to improve and extend people's lives.

< advertisement >

People are different and so are diseases.

That's why we are committed to discovering and developing personalised medicines and targeted diagnostic tests to help people live better, longer lives.



SUNDAY, 5 NOVEMBER

7:00-18:00 **REGISTRATION HELP DESK HOURS *Hall 5***

8:00-18:00 **EXHIBITOR SET UP *Hall 4***

12:00-18:00 **SPEAKER READY ROOM HOURS *Fyne (Loch Suite)***

8:00-17:00 **SHORT COURSE FULL DAY (Separate Registration Required)**

Bayesian Analysis – Overview and Applications *Dochart (Loch Suite)* 

Track: **Modeling Methods**

Level: **Intermediate** *This course is designed for those with a limited understanding of Bayesian statistical concepts or for those who want a refresher and more practical experience.*

Faculty: **Christopher S. Hollenbeak, PhD**, Penn State College of Medicine, Hershey, PA, USA; **Keith R Abrams, PhD**, University of Leicester, Leicester, UK

8:00-12:00 **SHORT COURSE MORNING SESSION (Separate Registration Required)**

NEW! US Payers – An Introduction to Their Structures, Evidence Needs, and Decision-Making Process *Hall 2*

Track: **Use of Pharmacoeconomic / Economic / Outcomes Research Information**

Level: **Introductory** *This course is designed for those having very minimal experience in understanding differences in perspectives and evidence needs for various access decision makers in the US Health Care system.*

Faculty: **Priti Jhingran, PhD**, Allergan, Jersey City, NJ, USA; **Helen Sherman, PharmD, RPh**, Solid Benefit Guidance, Portland, OR, USA

Using DICE Simulation for Health Economic Analyses *Carron (Loch Suite)*

Track: **Modeling Methods**

Level: **Introductory** *This course is designed for those with some familiarity with modeling.*

Faculty: **J. Jaime Caro, MDCM, FRCPC, FACP**, Evidera, Waltham, MA, USA and McGill University, Montreal, QC, Canada; **Jorgen Moller, MSc, Mech Eng**, Evidera, Hammersmith, UK

Use of Instrumental Variables in Observational Studies of Treatment Effects *Gala (Armadillo)* 

Track: **Observational Data Methods**

Level: **Intermediate** *This course is suitable for those with some knowledge of econometrics.*

Prereq.: *Previous attendance at the ISPOR short course, "Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources," or equivalent knowledge, is recommended.*

Faculty: **Benjamin M. Craig, PhD**, University of South Florida and Moffitt Cancer Center, Tampa, FL, USA; **Bradley C. Martin, PharmD, PhD, RPh**, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA; **Antoine C. El Khoury, PhD, MS**, Janssen GCC, Dubai, United Arab Emirates

Transferability and Relevance of Cost-Effectiveness Data Between Countries *Alsh (Loch Suite)*

Track: **Economic Methods**

Level: **Advanced** *This course is for those with advanced understanding of economic evaluations of health care programs and experience in the critical assessment of cost-effectiveness studies.*

Faculty: **Manuela A. Joore, PhD**, Care and Public Health Research Institute (CAPHRI) and Maastricht University, Maastricht, The Netherlands; **Silvia Evers, PhD, LLM**, Maastricht University, Maastricht, The Netherlands

NEW! Mapping to Estimate Utility Values from Non-Preference Based Outcome Measures *Boisdale (Loch Suite)*

Track: **Patient Preference Methods**

Level: **Intermediate**

Faculty: **Allan Wailoo, MA, MSc, PhD**, University of Sheffield, Sheffield, UK; **Mónica Hernández, MSc, PhD**, University of Sheffield, Sheffield, UK; **Andrea Manca, MSc, PhD**, University of York, Heslington, York, UK



Indicates hands-on exercises requiring the use of your personal computer.



Budget Impact Analysis I: A 6-Step Approach **Lomond Auditorium (Loch Suite)**

Track: **Economic Methods**

Level: **Intermediate** *This course is designed for those with some experience with pharmacoeconomic analysis.*

Faculty: **Stephanie R. Earnshaw, PhD, MS**, RTI Health Solutions, Research Triangle Park, NC, USA; **C. Daniel Mullins, PhD**, University of Maryland, School of Pharmacy, Baltimore, MD, USA; **Thor-Henrik Brodtkorb, PhD**, RTI Health Solutions, Ljungskile, Sweden

Risk-Sharing / Performance-Based Arrangements for Drugs and Other Medical Products **Forth (Armadillo)**

Track: **Use of Pharmacoeconomic / Economic / Outcomes Research Information**

Level: **Intermediate** *This course is designed for those with some experience with pharmacoeconomic analysis.*

Prereq.: *Helpful for those taking this course to have completed the ISPOR short course "Elements of Pharmaceutical/Biotech Pricing" or to be familiar with both the key determinants of pharmaceutical pricing and the main international health systems.*

Faculty: **Louis P. Garrison, PhD**, University of Washington, Seattle, WA, USA; **Adrian Towse, MA, MPhil**, Office of Health Economics, London, UK; **Josh J. Carlson, MPH, PhD**, University of Washington, Seattle, WA, USA

Understanding Survival Modeling with Application to Health Technology Assessment **Hall 1**

Track: **Modeling Methods**

Level: **Intermediate**

Faculty: **Andrew Briggs, DPhil**, University of Glasgow, Glasgow, UK; **Christopher Parker, MSc**, Celgene Ltd., Uxbridge, UK; **Andrew Davies, MSc**, University of Glasgow, Glasgow, UK; **Gemma Kay, MSc**, ICON Health Economics & Epidemiology, Abingdon, UK

10:00-10:15 **COFFEE BREAK**

Coffee Break Sponsored by PHMR

PHMR

12:00-13:00 **LUNCH** (*Attendees on their own*)

13:00-17:00 **SHORT COURSE AFTERNOON SESSION** (*Separate Registration Required*)

Budget Impact Analysis II: Applications & Design Issues **Lomond Auditorium (Loch Suite)**



Track: **Economic Methods**

Level: **Intermediate** *This course is designed for those who have basic knowledge of budget impact analyses and desire exposure to these analyses in Excel.*

Prereq.: *Participation in the ISPOR short course "Introduction to Budget Impact Analysis: A 6-Step Approach," or equivalent knowledge, is recommended. Knowledge of Excel is highly recommended.*

Faculty: **Stephanie R. Earnshaw, PhD, MS**, RTI Health Solutions, Research Triangle Park, NC, USA; **Anita J. Brogan, PhD**, RTI Health Solutions, Research Triangle Park, NC, USA; **Thor-Henrik Brodtkorb, PhD**, RTI Health Solutions, Ljungskile, Sweden

Advanced Methods for Addressing Selection Bias in Real-World Effectiveness and Cost-Effectiveness Studies **Boisdale (Loch Suite)**



Track: **Observational Data Methods**

Level: **Intermediate**

Faculty: **Richard Grieve, PhD**, London School of Hygiene and Tropical Medicine, London, UK; **Noemi Kreif, PhD**, London School of Hygiene and Tropical Medicine, London, UK

Introduction to the Economic Analysis of Diagnostics **Gala (Armadillo)**

Track: **Use of Pharmacoeconomic / Economic / Outcomes Research Information**

Level: **Intermediate**

Faculty: **John E. Schneider, PhD**, Avalon Health Economics, Morristown, NJ, USA; **Andrew Briggs, DPhil**, University of Glasgow, Glasgow, UK

Network Meta-Analysis in Relative Effectiveness Research **Carron (Loch Suite)**

Track: **Outcomes Research Methods**

Level: **Intermediate** *This course requires at least a basic knowledge of meta-analysis and statistics.*

Faculty: **Jeroen P. Jansen, PhD, MSc**, Chief Scientist, Precision XTract, Oakland, CA, USA; **Steve KanTERS, MSc**, Precision XTract, Vancouver, BC, Canada



Indicates hands-on exercises requiring the use of your personal computer.



Risk-Sharing/Performance-Based Arrangements in Central & Eastern Europe: Implementation of Managed Entry Agreements *Hall 1*



Track: **Use of Pharmacoeconomic / Economic / Outcomes Research Information**

Level: **Intermediate**

Faculty: **Zoltán Kaló, PhD**, Eötvös Loránd University, Budapest, Hungary; **Rok Hren, PhD, MSc IHP (HE)**, University of Ljubljana, Ljubljana, Slovenia; **Katarzyna Kolasa, PhD**, GHEOR4MEDICALDEVICES and Medical University of Warsaw, Warsaw, Poland

Adjusting for Time-Dependent Confounding and Treatment Switching Bias in Observational Studies and Clinical Trials: Purpose, Methods, Good Practices and Acceptance in Health Technology Assessment *Forth (Armadillo)*

Track: **Observational Data Methods**

Level: **Intermediate**

Faculty: **Uwe Siebert, MD, MPH, MSc, ScD**, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria; **Nicholas Latimer, MSc, PhD**, University of Sheffield, Sheffield, UK; **Felicitas Kühne, MSc**, UMIT, Hall i.T., Austria

Reimbursement Systems for Pharmaceuticals in Europe *Hall 2*

Track: **Use of Pharmacoeconomic / Economic / Outcomes Research Information**

Level: **Intermediate** *This course is designed for individuals with intermediate experience within a single health care system wishing to broaden their appreciation of other reimbursement systems.*

Faculty: **Mondher Toumi, MD, PhD, MSc**, Aix-Marseille University, Marseille, France

Using Multi-Criteria Decision Analysis in Health Care Decision Making: Approaches & Applications *Alsh (Loch Suite)*

Track: **Use of Pharmacoeconomic / Economic / Outcomes Research Information**

Level: **Introductory** *The course is designed for those unfamiliar with MCDA, but who have a basic understanding of other evaluation methodologies.*

Faculty: **Maarten J. IJzerman, PhD**, University of Twente, Enschede, The Netherlands; **Kevin Marsh, PhD**, Evidera Ltd, London, UK; **Nancy Devlin, PhD**, Office of Health Economics, London, UK

15:00-15:15 **COFFEE BREAK**

17:30-18:30 **EDUCATIONAL SYMPOSIUM (Open to all attendees) *Lomond Auditorium (Loch Suite)***

Evaluating Survival Benefits in Technology Appraisals of Innovative Oncology Drugs: Challenges and Practical Solutions

Moderator: Jipan Xie, MD, PhD, Analysis Group, Inc., Los Angeles, CA, USA

Speakers: Nicholas Latimer, PhD, SchARR - University of Sheffield, Sheffield, UK; **Zheng-Yi Zhou, PhD**, Analysis Group, Inc., London, UK

(Sponsored by Analysis Group)



18:45-19:45 **EDUCATIONAL SYMPOSIUM (Open to all attendees) *Lomond Auditorium (Loch Suite)***

How to Use the BEACON Framework to Help Guide the Drug Development Process and Achieve Patient Access

Moderator: Meindert Boysen, PharmD, MSc, National Institute for Health and Care Excellence, Manchester, UK

Speaker: William Dunlop, MSc, Mundipharma International Ltd, Cambridge, UK; **Andrew Walker, PhD**, Salus Alba Consulting, Glasgow, UK; **Ron Goeree, MA**, McMaster University and Goeree Consulting Ltd, Hamilton, ON, Canada

(Sponsored by Mundipharma International Ltd)





MONDAY, 6 NOVEMBER

7:00-18:00 **REGISTRATION HELP DESK HOURS *Hall 5***7:15-8:30 **ISPOR NUTRITION ECONOMICS SPECIAL INTEREST GROUP OPEN MEETING *Forth (Armadillo)***7:30-8:30 **ISPOR PATIENT REPORTED OUTCOMES RESEARCH SPECIAL INTEREST GROUP OPEN MEETING *Hall 1***7:30-8:30 **EDUCATIONAL SYMPOSIUM *Lomond Auditorium (Loch Suite)*****Real-World Evidence to Support Regulatory Approvals Based on Tumor Biomarkers in Oncology Research****Moderator: Bruce Feinberg, DO**, Cardinal Health Specialty Solutions, Dublin, OH, USA**Speakers: Bjorn Bolinder, MBA**, AstraZeneca, Gaithersburg, MD, USA; **Hui Huang, PhD, MBA**, Takeda, Cambridge, MA, USA; **Samuel Wagner, PhD, RPh**, Bristol-Myers Squibb, Washington Crossing, PA, USA*(Sponsored by Cardinal Health)*8:00-18:00 **SPEAKER READY ROOM HOURS *Fyne (Loch Suite)***8:30-19:45 **EXHIBIT/POSTER HALL HOURS *Hall 4***8:45-13:45 **RESEARCH POSTERS - SESSION I *Hall 4***8:45-10:45 **WELCOME & FIRST PLENARY SESSION *Clyde Auditorium (Armadillo)*****WELCOME FROM ISPOR CEO/EXECUTIVE DIRECTOR****Nancy S. Berg, BSc**, International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ, USA**PRESIDENTIAL ADDRESS****Shelby D. Reed, RPh, PhD**, Duke University, Durham, NC, USA**CONGRESS PROGRAM OVERVIEW FROM PROGRAM COMMITTEE CO-CHAIRS****Andrew Briggs, DPhil**, University of Glasgow, Glasgow, UK**Maarten IJzerman, PhD**, University of Twente, Enschede, The Netherlands**FIRST PLENARY SESSION: Where is the Value in Value-Based Health Care?****Moderator: Maarten J. IJzerman, PhD**, University of Twente, Enschede, The Netherlands**Speakers: Peter Naredi**, University of Gothenburg and European CanCer Organization (ECCO), Brussels, Belgium; **Luke Slawomirski**, Organisation for Economic Co-operation and Development (OECD), Paris, France; **Bettina Ryll, MD, PhD**, Melanoma Patient Network Europe and European Society for Medical Oncology (ESMO), Uppsala, Sweden; **Jason Arora, MD, MPH**, Medtronic, Watford, UK10:45-11:15 **BREAK, EXHIBITS & RESEARCH POSTERS - SESSION I *Hall 4***11:15-12:15 **BREAKOUT SESSION****IP1: Pragmatic Clinical Trials to Estimate Treatment Effects: Are They Worth the Effort? *Hall 3*****Moderator: Rita M. Kristy, MS**, Astellas Pharma Global Development, Northbrook, IL, USA**Panelists: Keith R. Abrams, PhD, CStat**, University of Leicester, Leicester, UK; **Christoph Gerlinger, PD**, Bayer AG, Berlin, Germany; **Helene Karcher, PhD**, Analytica Laser, Loerrach, Germany**IP2: How to Improve Consistency of Orphan Drug Pricing and Reimbursement in Europe? Application of the 'Orph-Val' Principles in Germany, France, and the United Kingdom *Clyde Auditorium (Armadillo)*****Moderator: Lieven Annemans, PhD, MSc**, Ghent University - Brussels University, Ghent, Belgium**Panelists: Karina Ehrig, PhD**, Federal Joint Committee (G-BA), Berlin, Germany; **Francois Meyer, PhD**, Haute Autorité de Santé (HAS), Saint-Denis, France; **Sheela Upadhyaya, MSc**, National Institute for Health and Care Excellence (NICE), London, UK**W1: Where Do We Need Good Research Practice Guidance in Health Technology Assessment? *Hall 2*****Discussion Leaders: Finn Børllum Kristensen, MD, PhD**, University of Southern Denmark, Hilleroed, Denmark; **Mirjana Huić, MD, PhD**, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia; **Wim Goettsch, PhD**, The National Healthcare Institute (ZIN), Diemen, The Netherlands; **Sophie Werkö, PhD, MSc**, Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden



W2: Patient Powered Registries: Useful for Health Technology Assessment or Not? Hall 1

Discussion Leaders: **Gurmit Sandhu, B Pharm (Hons), MBA, MPH**, Gurmit Sandhu Consulting GmbH, Basel, Switzerland; **Elisabeth M. Oehrlein, BA**, University of Maryland School of Pharmacy, Baltimore, MD, USA; **Robert N. McBurney, PhD**, Accelerated Cure Project for MS, Waltham, MA, USA; **Chantal Guilhaume, PharmD**, Haute Autorité de Santé, Saint-Denis La Plaine, France

P1: Cost-Effectiveness Studies Lomond Auditorium (Loch Suite)

CE1 Cost-Effectiveness of Dabigatran With Real World Effectiveness Evidence

11:15-11:30 **de Pourville G¹**, Guilmet C², Cohen AA³, Le Dissez C⁴, Luciani L⁴, Le Lay K⁴, ¹ESSEC Business School, Cergy-Pontoise, France, ²MAPI Group, Nanterre, France, ³Hôpital saint Antoine, Paris, France, ⁴Boehringer Ingelheim France, Paris, France

CE2 Cost-Effectiveness Analysis of Midostaurin (Mido) With Standard Chemotherapy (SOC) for Acute Myeloid Leukemia (AML) in the United Kingdom (UK)

11:30-11:45 Tremblay G¹, Dolph M¹, Patel S², Brandt P³, **Forsythe A¹**, ¹Purple Squirrel Economics, New York, NY, USA, ²Novartis Pharmaceuticals UK Limited, Camberley, Surrey, UK, ³Novartis Pharmaceuticals, East Hanover, NJ, USA

CE3 First-Line Pembrolizumab in PD-L1 Positive Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis From a UK Healthcare Perspective

11:45-12:00 **Hu X**, Goldman DP, University of Southern California, Los Angeles, CA, USA

CE4 The Effectiveness and Cost-Effectiveness of Tobacco Control Mass Media Campaigns in Scotland

12:00-12:15 **Hagpanahan H¹**, Boyd KA¹, Mackay DF¹, Mcintosh E¹, Pell J¹, Haw S², ¹University of Glasgow, Glasgow, UK, ²University of Stirling, Stirling, UK

P2: Cancer Studies Forth (Armadillo)

CN1 Use of New Therapies and Hospital Admission Near the End of Life in Castration Resistant

11:15-11:30 **Prostate Cancer (CRPC) in the Castration Resistant Prostate Cancer Registry (CAPRI) in The Netherlands**

Kuppen M¹, Westgeest H¹, Van den Eertwegh A², Gerritsen W³, Uyl - de Groot C¹, ¹Erasmus University Rotterdam, Rotterdam, The Netherlands, ²VU University Medical Centre, Amsterdam, The Netherlands, ³Radboud University Medical Center, Nijmegen, The Netherlands

CN2 The Greta Study: Generating Real-World Evidence About Bevacizumab Treatment of Metastatic Colorectal Cancer by Linking Cancer Registries and Healthcare Databases in Italy

11:30-11:45 Franchi M¹, **Caputo A²**, Barni S³, De Ceglie MC⁴, Mazzucco W⁵, Ricci P⁶, Tagliabue G⁷, Tumino R⁸, Corrao G⁹, ¹University of Milano-Bicocca, Milano, Italy, ²Roche S.p.A., Monza, Italy, ³ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, Italy, ⁴Roche S.p.A, Monza, Italy, ⁵University of Palermo, Palermo, Italy, ⁶Health Protection Agency Mantua&Cremona, NHS Italy, Mantova, Italy, ⁷Fondazione IRCCS National Cancer Institute, Milano, Italy, ⁸Provincial Health Authority, ASP Ragusa, Ragusa, Italy, ⁹Università di Milano-Bicocca, Milan, Italy

CN3 Assessing the Consistency in Reporting of Adverse Events Across Data Sources for Multiple Myeloma Treatment

11:45-12:00 **Kish J¹**, Feinberg B², ¹Cardinal Health Specialty Solutions, Dallas, TX, USA, ²Cardinal Health, Dublin, OH, USA

CN4 Utilization and Treatment Patterns Among Patients With Advanced Non-Small Cell Lung Cancer Receiving Predictive Molecular Biomarker (BMX) Tests

12:00-12:15 **Kothari S¹**, Arunachalam A², Tsao M³, Lee DH⁴, Kambartel K⁵, Isobe H⁶, Huang M⁷, Escosteguy Barrios CH⁸, Khattak A⁹, de Marinis F¹⁰, Cao X¹¹, Burke T¹², Lopez MA¹³, De Castro J¹⁴, ¹Merck & Co, Kenilworth, NJ, USA, ²Merck & Co., Inc., North Wales, PA, USA, ³University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada, ⁴Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South), ⁵Bethanien Hospital, Moers, Germany, ⁶KKR Sapporo Medical Center, Sapporo, Japan, ⁷Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan, ⁸PUCRS School of Medicine, Porto Alegre, Brazil, ⁹Fiona Stanley Hospital, Murdoch, Australia, ¹⁰European Institute of Oncology, Milan, Italy, ¹¹Merck & Co, Inc, Kenilworth, NJ, USA, ¹²Merck & Co., Inc., Lebanon, NJ, USA, ¹³MSD, Madrid, Spain, ¹⁴Hospital Universitario La Paz, MADRID, Spain

12:15-14:15 **LUNCH, EXHIBITS & RESEARCH POSTERS - SESSION I Hall 4**

Lunch Sponsored by Health Economics and Outcomes Research Ltd.



12:30-13:30 **ISPOR DIGEST OF DATABASES SPECIAL INTEREST GROUP OPEN MEETING Hall 1**

12:45-13:45 **ISPOR STUDENT RESEARCH SHOWCASE Lomond Auditorium (Loch Suite)**

Moderators: **Zeba Khan, MS, RPh, PhD**, Celgene Corporation, Summit, NJ, USA; **Laura Pizzi, MPH, RPh, PharmD**, Rutgers University, Piscataway, NJ, USA

Speakers: **Natalie J. Williams, Msc**, NIHR Nottingham Hearing Biomedical Research Unit, Nottingham, UK; **Junjie Ma, Msc**, University of Utah, Salt Lake City, UT, USA; **Omer Ben-Aharon, MBA, MHA**, Bar-Ilan University, Ramat Gan, Israel; **Fanni Soikkeli**, University of Eastern Finland, Joensuu, Kuopio and Savonlinna, Finland

12:45-13:45 **EDUCATIONAL SYMPOSIUM *Clyde Auditorium (Armadillo)*****HTA V2.0: The Relevance of Real-World Evidence in Value Frameworks and Its Relation with Regulatory and Health Technology Assessment Convergence**Moderator: **Jacco Keja, PhD**, IQVIA, London, UKSpeakers: **Maureen Rutten-van Mólken, PhD, MSc**, Erasmus School of Health Policy & Management (ESHPM), Rotterdam, The Netherlands; **Dana Vigier, MD, BMS**, Rueil-Malmaison, France; **Elizabeth Powers, MBA**, IQVIA, New York, NY, USA

(Sponsored by IQVIA)

12:45-13:45 **POSTER AUTHOR DISCUSSION HOUR - SESSION I Hall 4**14:15-15:15 **BREAKOUT SESSION****IP3: Unmet (Medical) Need: Should Stakeholders Align on a Definition? Hall 2**Moderator: **Claudine Sapede, PharmD, MSc**, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPanelists: **Hans-Georg Eichler, MD, MSc**, European Medicines Agency, London, UK; **Nicola Bedlington**, The Patient Access Partnership PACT, Brussels, Belgium; **Jo De Cock, MS**, INAMI - Institut National de l'Assurance Maladie-Invalidité, Brussels, Belgium**IP4: Value Added Medicines: Time to Adjust the Health Technology Assessment Decision Frameworks? Clyde Auditorium (Armadillo)**Moderator: **Michael Drummond, MCom, DPhil**, University of York, Heslington, York, UKPanelists: **Pascal Auquier, MD**, Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France;**Luigi Burgio, MSc**, Teva Italia S.r.l., Assago (MI), Italy; **Mondher Toumi, MD, PhD, MSc**, Aix-Marseille University, Marseille, France**W3: Making Patient Reported Outcomes Measurement Meaningful: Best Practices for Presenting Patient Reported Outcomes Data to Patients, Clinicians, and Decision Makers Hall 3**Discussion Leaders: **Jakob B. Bjorner, MD, PhD**, Optum Patient Insights, Johnston, RI, USA; **Michael Brundage, MSc, FRCPC, MD**, Queen's University, Kingston, ON, Canada; **Claire Snyder, MHS, PhD**, Johns Hopkins School of Medicine, Baltimore, MD, USA; **Martha Bayliss, MSc**, Optum Patient Insights, Johnston, RI, USA**W4: Bridging the Gap: Best Practices in Navigating Diverging Perceptions of Regulators and Payers on Non-Traditional Clinical Trial Endpoints Forth (Armadillo)**Discussion Leaders: **Mark Chalmers, PhD**, CBPartners, London, UK; **Caroline Solon, MSc**, CBPartners, San Francisco, CA, USA; **Andrew Walker, PhD**, Salus Alba Consulting, Glasgow, UK; **Lung-I Cheng, PhD**, Takeda, Zurich, Switzerland**P3: Studies on Health Technology Assessment Agencies Lomond Auditorium (Loch Suite)****HT1 Playing in the Same Pond - The Impact of Brexit on Clinical Trials and Access**14:15-14:30 **Wang GD**, Macaulay R, PAREXEL International, London, UK**HT2 Health Technology Assessment Decisions in Immuno-Oncology Therapies: Results, Rationales, and Trends**14:30-14:45 **Campbell CM**, Nguyen VB, Clark RS, Meyer KL, Xcenda, LLC, Palm Harbor, FL, USA**HT3 Analysis of Factors Influencing the Level of Actual Benefit in Health Technology Assessment**14:45-15:00 **Bouschon M¹**, Li J², Barthelemy C³, ¹Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France, ²Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France, ³Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France**HT4 Using Real-World Data (RWD) in Health Technology Assessment (HTA) Practice: A Comparative Study of 5 HTA Agencies**15:00-15:15 **Makady A¹**, van Veelen A², Jonsson P³, Moseley O⁴, D'Andon A⁵, de Boer A², Hillege JL⁶, Klungel O², Goettsch W⁷, ¹The National Healthcare Institute (ZIN), Diemen, The Netherlands, ²Utrecht University, Utrecht, The Netherlands, ³National Institute for Health and Care Excellence (NICE), Manchester, UK, ⁴Scottish Medicines Consortium, 50 West Nile Street, UK, ⁵French National Authority for Health, Saint Denis La Plaine, France, ⁶University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, ⁷Utrecht University, UTRECHT, The Netherlands**P4: Research on Methods Hall 1****RM1 Network Meta-Analysis of Hazard Ratios Vs. Fractional Polynomials Approach in a Cost-Effectiveness****Analysis Considering Advanced Gastric Cancer**14:15-14:30 **Cranmer HL**, Harvey RC, Tolley Health Economics Ltd., Buxton, UK**RM2 Multivariate Network Meta-Analysis of Survival Function Parameters**14:30-14:45 **Cope S¹**, Chan K¹, Jansen JP², ¹Precision Health Economics, Vancouver, BC, Canada, ²Precision Health Economics, Los Angeles, CA, USA**RM3 Methods for Extracting Treatment Patterns for Renal Cell Carcinoma (RCC) From Social Media (SM)****Forums Using Natural Language Processing (NLP) and Machine Learning (ML)**14:45-15:00 **Merinopoulou E¹**, Ramagopalan S², Malcolm B², Cox A¹, ¹Evidera, London, UK, ²Bristol-Myers Squibb, Uxbridge, UK**RM4 Non-Proportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis**15:00-15:15 **Gsteiger S¹**, Windisch R¹, Bryden P¹, Wiksten A², ¹F. Hoffmann-La Roche Ltd, Basel, Switzerland, ²StatFinn & EPID Research, Espoo, Finland



15:00-16:00 CAREER ADVICE ACROSS THE GLOBE - THE ART OF GETTING PUBLISHED *Alsh (Loch Suite)*
Speakers: **Lyn Beamesderfer**, International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ, USA; **C. Daniel Mullins, PhD**, University of Maryland School of Pharmacy, Baltimore, MD, USA; **Diego Rosselli, MD, MEd, MHP**, Pontificia Universidad Javeriana, Bogotá, Colombia; **Dan Greenberg, PhD**, Ben-Gurion University of the Negev, Beer-Sheva, Israel

15:15-15:45 BREAK & EXHIBITS *Hall 4*
Coffee Break Sponsored by Ingress Health



15:45-16:45 BREAKOUT SESSION

IP5: European HTA 2020: What is the Road Map to Effective Permanent Cooperation? (Invited Issue Panel) *Hall 2*

Moderator: **Tim Wilsdon**, Charles Rivers Associates, London, UK

Panelists: **Wim Goettsch**, EUnetHTA JA3 Directorate, The National Healthcare Institute (ZIN), Diemen, The Netherlands; **Adrian Griffin**, Johnson & Johnson, Buckinghamshire, UK; **Nicola Bedlington**, European Patients Forum (EPF), Brussels, Belgium; **Flora Giorgio**, Directorate General for Health and Food Safety (DG SANTE), European Commission, Brussels, Belgium

IP6: Are Existing Health Technology Assessment Requirements Inadequate for Establishing Value for Potentially Transformative Gene Therapies? *Hall 3*

Moderator: **Kellie Meyer, PharmD, MPH**, Xcenda, Palm Harbor, FL, USA

Panelists: **Ron Akehurst, PhD**, BresMed Health Solutions, Sheffield, UK; **Clark Paramore, MSPH**, bluebird bio, Cambridge, MA, USA; **Adrian Towse, MA, MPhil**, Office of Health Economics, London, UK

W5: Sustainable Funding and Fair Pricing for Orphan Drugs: What Are the Solutions? *Lomond Auditorium (Loch Suite)*

Discussion Leaders: **Martina Garau, MSc**, Office of Health Economics, London, UK; **Michael Drummond, MCom, DPhil**, University of York, Heslington, York, UK; **Saskia Knies, PhD**, National Health Care Institute (ZiN), Diemen, The Netherlands; **Ulf Staginnus, MBA**, Shire plc, Zug, Switzerland

W6: Generating Real-World Evidence for Real-World Decisions: Application of Advanced Methods *Clyde Auditorium (Armadillo)*

Discussion Leaders: **Mark Sculpher, PhD**, University of York, York, UK; **Richard Grieve, PhD**, London School of Hygiene and Tropical Medicine, London, UK; **Anirban Basu, PhD**, University of Washington, Seattle, WA, USA; **Stephen Oneill, MEconSc PhD**, National University of Ireland, Galway, Galway, Ireland

P5: Medication Adherence Studies *Hall 1*

AD1 Exploring Factors Explaining Treatment Acceptance in Patients Suffering From a Chronic Disease

15:45-16:00 Wiederkehr S¹, de Bock E², Chekroun M³, **Arnould B⁴**, ¹Mapi, Patient Centered Sciences, Lyon, France, ²Mapi, Patient-Centered Outcomes, Lyon, France, ³Carenity, Paris, France, ⁴Mapi, Patient Centered Outcomes, Lyon, France

AD2 The Impact of Pharmacist-Led Medication Therapy Management on Medication Adherence in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Study

16:00-16:15 **Erku DA**, Belachew SA, Tegegn HG, Ayele AA, University of Gondar, Gondar, Ethiopia

AD3 Factors Associated With an Adherence With Antiepileptic Drugs in Children Treated in Pediatric Practices in Germany

16:15-16:30 Kostev K¹, **Dombrowski S¹**, Jacob L², ¹QuintilesIMS, Frankfurt am Main, Germany, ²University of Paris 5, Paris, France

AD4 Predictive Analysis for Identifying Patient Characteristics Associated With Primary Medication Nonadherence for Lipid Lowering Therapies

16:30-16:45 Hill JW¹, **Rane PB²**, Hines DM¹, Patel J², Harrison DJ², Wade RL¹, ¹QuintilesIMS, Plymouth Meeting, PA, USA, ²Amgen Inc., Thousand Oaks, CA, USA

P6: Mental Health Studies *Forth (Armadillo)*

MH1 Discrete Event Simulation Modelling of Long Term Cost-Effectiveness of Internet-Based Blended Cognitive Behavioural Therapy for Major Depressive Disorder: Extrapolation of the E-Compared Randomised Controlled Trial

15:45-16:00 **O'Connell MM¹**, Kolovos S², Bosmans JE², Forbes JF¹, E-COMPARED Consortium³, ¹University of Limerick, Limerick, Ireland, ²Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, ³E-COMPARED Consortium, Europe, Ireland

MH2 Adherence Patterns Among Patients Using Oral Atypical Antipsychotics and Other Medications

16:00-16:15 **Shafrin J¹**, Lakdawalla DN², MacEwan JP¹, Silverstein AR¹, Hatch A³, Forma F⁴, ¹Precision Health Economics, Los Angeles, CA, USA, ²University of Southern California, Los Angeles, CA, USA, ³ODH, Inc., Princeton, NJ, USA, ⁴Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA

MH3 Model Structure of Patient-Level Models for Schizophrenia: A Systematic Literature Review

16:15-16:30 **Zhou J¹**, Millier A², Dorey J², Aballéa S², Toumi M¹, ¹Aix-Marseille University, Marseille, France, ²Creativ-Ceutical, Paris, France

MH4 Family Caregiving in Dementia and Its Impact on Quality of Life and Economic Burden in Japan – Web-Based Survey

16:30-16:45 **Igarashi A¹**, Fukuda A¹, Teng L¹, Ma F², Dorey J³, Onishi Y⁴, ¹University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, ²Creativ-Ceutical, Beijing, China, ³Creativ-Ceutical, Paris, France, ⁴Creativ-Ceutical K.K., Tokyo, Japan



15:45-19:30 RESEARCH POSTERS - SESSION II Hall 4

17:00-18:00 BREAKOUT SESSION

IP7: 'Mind the Gap!': How Should We Manage the Difference Between Regulatory and Reimbursement Evidence Requirements for Medical Devices? *Clyde Auditorium (Armadillo)*

Moderator: Bjoern Schwander, AHEAD GmbH (Agency for Health Economic Assessment and Dissemination), Lörrach, Germany
Panelists: Richard Charter, MSc, Becton Dickinson, Basel, Switzerland; Karen Facey, PhD, University of Edinburgh, Edinburgh, UK; Nneka C. Onwudiwe, PhD, PharmD, MBA, FDA, Silver Spring, MD, USA

IP8: Forecasting Pharmaceutical Expenditure in Europe: Is It Sustainable? *Lomond Auditorium (Loch Suite)*

Moderator: Jorge Mestre-Ferrandiz, PhD, Independent Economics Consultant, Madrid, Spain
Panelists: Tim Davis, MSc, IQVIA, Basel, Switzerland; Claudio Jommi, PhD, SDA Bocconi School of Management, Milano, Italy; Panos Kanavos, PhD, London School of Economics and Political Science, London, UK

W7: Value of Information (VOI) Analysis for Research Decisions: Emerging Good Practice Recommendations From the ISPOR VOI Task Force *Hall 2*

Discussion Leaders: Elisabeth Fenwick, PhD, MSc, ICON plc, Abingdon, UK; Saskia Knies, PhD, National Health Care Institute (ZiN), Diemen, The Netherlands; Hendrik Koffijberg, PhD, University of Twente, Enschede, The Netherlands; Claire Rothery, PhD, University of York, York, UK

W8: Modeling Separate Lines of Treatment Versus Treatment Sequences in Cancer *Hall 3*

Discussion Leaders: Agnes Benedict, MSc, Evidera, Budapest, Hungary; Matthew Stevenson, PhD, University of Sheffield, Sheffield, UK; Sonja Sorensen, MPH, Evidera, Bethesda, MD, USA

P7: Conceptual Papers *Hall 1*

CP1 Innovative Pricing and Reimbursement Schemes – The What, Why, Which, and How

17:00-17:15 **Macaulay R**, Hettle R, PAREXEL International, London, UK

CP2 Using Outcome Data to Inform Healthcare Professional – Patient Discussion: A Database of Treatment Effects

17:15-17:30 **Gilbert J**, National Guideline Centre, London, UK

CP3 The Future of Precision Medicine: What Does It Mean for NICE?

17:30-17:45 **Rejon-Parrilla JC¹**, Lovett RE², Chalkidou A³, Love-Koh J⁴, Wood H⁴, Ennis K⁴, Peel A⁴, Taylor M⁴, ¹National Institute for Health and Care Excellence (NICE), Manchester, UK, ²National Institute for Health and Care Excellence (NICE), London, UK, ³King's Technology Evaluation Centre (KiTEC), King's College London, London, UK, ⁴York Health Economics Consortium, University of York, York, UK

CP4 Challenges in Optimising Real World Evidence for Alzheimer's Disease

17:45-18:00 **Reed C¹**, de Reydet de Vulpillieres F², Gallacher J³, ¹Eli Lilly and Company Ltd, Windlesham, UK, ²NOVARTIS PHARMA AG, Basel, Switzerland, ³Oxford University, Oxford, UK

P8: Cardiovascular Studies *Forth (Armadillo)*

CV1 Interim Results of a Multi-Country Survey to Evaluate Productivity Loss and Indirect Costs After

Cardiovascular Events in Europe

Gerlier L¹, Sidelnikov E², Kutikova L², Lamotte M¹, Amarenco P³, Kotseva K⁴, Annemans L⁵, ¹QuintilesIMS, Zaventem, Belgium, ²Amgen (Europe) GmbH, Zug, Switzerland, ³Bichat Hospital-Claude Bernard, Paris, France, ⁴National Heart & Lung Institute, Imperial College London, London, UK, ⁵Ghent University - Brussels University, Ghent, Belgium

CV2 A Framework for the Cost-Effectiveness Analysis of Novel Biomarker Testing in Cardiovascular Disease

17:15-17:30 **Kohli-Lynch CN**, Boyd K, Briggs A, Delles C, University of Glasgow, Glasgow, UK

CV3 CYP2C19 Guided Antiplatelet Therapy: A Cost-Effectiveness Analysis of 30-Day and One-Year Outcomes

Following Percutaneous Coronary Intervention

17:30-17:45 **Dong OM¹**, Borse MS¹, Polasek MJ², Farley JF¹, Stouffer GA¹, Lee CR¹, ¹University of North Carolina, Chapel Hill, NC, USA, ²QuintilesIMS, Durham, NC, USA

CV4 Cost Model for a New Acoustic Diagnostic Aid to Rule Out Coronary Artery Disease

17:45-18:00 Winther S¹, Böttcher M², **Wahler S³**, Bolin K⁴, ¹Aarhus University Hospital, Aarhus N, Denmark, ²Hjertemedicin Hjärtforskningssjukhuset, Helsingborg, Sweden, ³St. Bernward GmbH, Hamburg, Germany, ⁴University of Gothenburg, Gothenburg, Sweden

18:00-19:45 EXHIBITORS' OPEN HOUSE RECEPTION & RESEARCH POSTERS - SESSION II Hall 4

ISPOR wishes to thank the Lord Provost & Glasgow City Council for their ongoing assistance, and for their generosity in providing a special welcome drink at Monday evening Exhibitor Reception.

Reception Sponsored by Complete HEOR Solutions (CHEORS)





18:15-19:15 **BREAKOUT SESSION**

F1: Better, Cheaper, Faster: A Report on the Science of Optimization From the ISPOR Optimization Task Force *Hall 3*

Moderator: Alec Morton, PhD, University of Strathclyde, Glasgow, Scotland, UK

Speakers: Nasuh Buyukkaramikli, PhD, Erasmus University Rotterdam, Rotterdam, The Netherlands; Praveen Thokala, MSc, PhD, The University of Sheffield, Sheffield, UK; Jon Tosh, MSc, PhD, DRG Abacus, Manchester, UK

Presented by the ISPOR Optimization Task Force

F2: Methods and Preliminary Results of the ISPOR Oncology Health Economic Modeling Special Interest Group *Hall 2*

Moderator: Noemi Muszbek, MSc, Evidera, London, UK

Speakers: Agnes Benedict, MSc, Evidera, Budapest, Hungary; Sergio Iannazzo, MBA, SIHS Health Economics Consulting, Torino, Italy; Nermeen Nabil Ashoush, PhD, The British University in Egypt, Cairo, Egypt; Hena Qureshi, BSc, BA, University of Calgary, Calgary, AB, Canada

Presented by the Oncology Health Economic Modeling – Post-Progression Working Group of the ISPOR Oncology Special Interest Group

F3: Rare Disease Research, Health Technology Assessment and Evidence for Reimbursement *Clyde Auditorium (Armadillo)*

Moderator: Sandra Nestler-Parr, PhD, MPhil, MSc, Rare Access Ltd., London, UK

Speakers: Ken Redekop, PhD, Erasmus University Rotterdam, Rotterdam, The Netherlands; Christopher M. Blanchette, PhD, MBA, Precision Health Economics, Charlotte, NC, USA; Sheela Upadhyaha, BSc, National Institute for Health and Care Excellence, London, UK; Janis Clayton, BSc, PTC Therapeutics Ltd., Dublin, Ireland

Presented by the ISPOR Rare Disease Special Interest Group

F4: Could Multi-Stakeholder Partnership Improve Patient Access to Better Health Care in Latin America? *Hall 1*

Moderator: Ramiro E. Gilardino, MD, MSc, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), Lawrenceville, NJ, USA

Speakers: Diego F Guarin, MD, MPH, MA, Merck-Serono, Billerica, MA, USA; Diego Rosselli, MD, Pontificia Universidad Javeriana, Bogota, Colombia; Federico Augustovski, MD, MSc, PhD, University of Buenos Aires, Buenos Aires, Argentina; Nicola Bedlington, The Patient Access Partnership PACT, Brussels, Belgium

Presented by the Latin America Consortium

F5: Rare Diseases MCDA Criteria Implementation Results in European Countries *Lomond Auditorium (Loch Suite)*

Moderator: Olha Zaliska, PhD, DSci (Pharm), Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Speakers: John Yfantopoulos, PhD, University of Athens, Athens, Greece; Francesco Saverio Mennini, MSc, University Tor Vergata Roma, Rome, Italy; Tarik Catic, PhD(s), Health Economics and Pharmacoeconomics, Sarajevo, Bosnia; Rok Hren, PhD, MSc IHP(HE), Institute of Mathematics, Physics and Mechanics, Ljubljana, Slovenia

Presented by the ISPOR CEE Consortium and ISPOR Italy-Rome Chapter

F6: The Establishment of Negotiation Committee, Therapeutic Guidelines and Health Technology Assessment Efforts in CEE Countries *Forth (Armadillo)*

Moderator: Magda Hatzikou, PhD, Novartis Hellas SA, Athens, Greece

Speakers: Zoltan Kalo, PhD, Syreon Research Institute, Budapest, Hungary; Dragana Atanasijevic, MD, MSc, Institute of Public Health of Serbia, Belgrade, Serbia; Joanna Lis, PhD, Sanofi, Warsaw, Poland; Mary Geitona, MD, University of Peloponnese, Korinthos, Greece

Presented by the ISPOR CEE Consortium

18:15-19:15 **ISPOR STATED PREFERENCE METHODS SPECIAL INTEREST GROUP OPEN MEETING *Boisdale (Loch Suite)***

18:30-19:30 **POSTER AUTHOR DISCUSSION HOUR - SESSION II *Hall 4***

19:45-21:00 **ISPOR STUDENT AND NEW PROFESSIONALS MIXER *Mezzanine***

19:45-21:00 **ISPOR CENTRAL & EASTERN EUROPE (CEE) CONSORTIUM RECEPTION *Gala Foyer (Armadillo)***



TUESDAY, 7 NOVEMBER

7:00-18:00 **REGISTRATION HELP DESK HOURS** *Hall 5*

7:30-8:30 **EDUCATIONAL SYMPOSIUM** *Lomond Auditorium (Loch Suite)*

Changing the Health Technology Assessment Paradigm for Combination Therapies

Moderator: Mark Ratcliffe, PhD, PHMR Ltd, London, UK

Speakers: Andrew Walker, PhD, Salus Alba Consulting, Glasgow, UK; Claudio Jommi, MSc, CER GAS Bocconi University, Milan, Italy; Hanim Edoo, MSc, Medi-Qualite Omega, Paris, France; J. Jaime Caro, MDCM, FRCPC, FACP, Evidera, Bethesda, MD, USA

(Sponsored by Takeda Pharmaceuticals International AG)



7:45-8:45 **ISPOR BIOSIMILAR SPECIAL INTEREST GROUP OPEN MEETING** *Boisdale (Loch Suite)*

8:00-18:00 **SPEAKER READY ROOM HOURS** *Fyne (Loch Suite)*

8:30-19:15 **EXHIBIT/POSTER HALL HOURS** *Hall 4*

8:45-9:45 **BREAKOUT SESSION**

IP9: Should Rare Oncology Treatments Be Considered True Orphans? *Lomond Auditorium (Loch Suite)*

Moderator: Annabel Griffiths, PhD, Costello Medical Consulting Ltd, Cambridge, UK

Panelists: Elangovan Gajraj, MSc, National Institute for Health and Care Excellence, London, UK; Pan Pantziarka, PhD, Anti-Cancer Fund, Strombeek-Bever, Belgium; Ivana Cattaneo, MBA, Novartis Farma S.p.A, Origgio (VA), Italy

IP10: Does Valuation of Innovation in Appraisal of New Technologies Provide Appropriate Incentives for Manufacturers and Access for Patients? *Hall 2*

Moderator: Mark Sculpher, PhD, University of York, York, UK

Panelists: Karl Claxton, PhD, University of York, York, UK; Ross Maclean, MD, Precision Health Economics, Los Angeles, CA, USA; Jens Grueger, PhD, F. Hoffmann-LaRoche, Division Pharma, Basel, Switzerland

W9: Patients' Preferences in the European Regulatory Environment: A Critical Review *Forth (Armadillo)*

Discussion Leaders: Axel C. Mühlbacher, PhD, MBA, Hochschule Neubrandenburg, Neubrandenburg, Germany; Kevin Marsh, PhD, Evidera Ltd, London, UK; Janine A. van Til, PhD, University of Twente, Enschede, The Netherlands

W10: EQ-5D: Is NICE Ready for the Next Level? *Hall 3*

Discussion Leaders: Rosemary Lovett, PhD, National Institute for Health and Care Excellence (NICE), London, UK; Allan Wailoo, MA, MSc, PhD, University of Sheffield, Sheffield, UK; Nancy Devlin, PhD, Office of Health Economics, London, UK

P9: Medical Device & Diagnostics Studies *Hall 1*

MD1 Do We Know Enough Yet? A Cumulative Cost-Effectiveness Analysis of Mechanical Thrombectomy

8:45-9:00 **Teljeur C¹**, Ryan M², Glynn R³, Harrington P⁴, ¹Health Information and Quality Authority, Dublin, Ireland, ²Health Information and Quality Authority (HIQA), Dublin, Ireland, ³Health Service Executive, Dublin, Ireland, ⁴Health Information and Quality Authority, Dublin 7, Ireland

MD2 South West ICERs – The Experience of Nice's Diagnostics Assessment Programme

9:00-9:15 **Nixon F**, Walker T, Maloney J, Albrow R, National Institute for Health and Care Excellence, Manchester, UK

MD3 Cost-Effectiveness of Diagnosis: From Tests to Long-Term Outcomes and Costs

9:15-9:30 **Faria R¹**, Soares M², Spackman E³, Ahmed H⁴, Brown L⁵, Kaplan RS⁵, Emberton M⁶, Sculpher M², ¹University of York, Heslington, York, UK, ²University of York, York, UK, ³University of Calgary, Calgary, AB, Canada, ⁴Imperial College Healthcare NHS Trust, London, UK, ⁵MRC Clinical Trials Unit at UCL, London, UK, ⁶University College Hospitals NHS Foundation Trust, London, UK

MD4 Evaluating Matching-Adjusted Indirect Comparison and Simulated Treatment Comparison Techniques: Impact on Health-Related Quality of Life of Focussed Ultrasound Thalamotomy and Other Interventions for the Treatment of Medication-Refractory Essential Tremor

9:30-9:45 **Langford BE¹**, Ridley CJ¹, Beale RC², Marsh W¹, Caseby SC¹, Richard L³, ¹Costello Medical Consulting Ltd, Cambridge, UK, ²Costello Medical Consulting Ltd, London, UK, ³InSightec Ltd, Tirat Carmel, Israel

P10: Methods in Patient Preference Studies *Gala (Armadillo)*

PP1 Mimicking Real Life Decision-Making in Health: Allowing Respondents Time-To-Think in a Discrete Choice Experiment

8:45-9:00 **Veldwijk J¹**, Viberg Johansson J², Donkers B¹, de Bekker-Grob E¹, ¹Erasmus University Rotterdam, Rotterdam, The Netherlands, ²Uppsala University, Uppsala, Sweden



PP2 **Choice of Instrument Impacts Healthcare Decisions: Effect of Source of Utility Derived From the Same Patient Population on Cost-Effectiveness**

9:00-9:15

Gunsoy NB¹, Cockle SM², Doyle S², Asukai Y¹, ¹GSK, Uxbridge, UK, ²GSK, Brentford, Middlesex, UK

PP3 **The Comparative Performance of the CHU-9D and ADQOL Amongst Children Aged 5 Years or More With Eczema: Evidence From the Clothes Randomised Controlled Trial**

9:15-9:30

Sach TH¹, McManus E¹, Thomas K², Montgomery A², Harrison E², Williams H², on behalf of the CLOTHES trial team², ¹University of East Anglia, Norwich, UK, ²University of Nottingham, Nottingham, UK

PP4 **Does Using Factor Analysis to Select Covariates in Mapping Algorithms Improve Predictive Accuracy? A Case of Mapping the Core 23-Item Women's Health Questionnaire Onto the EQ-5D-5L and SF-6D**

9:30-9:45

Kaambwa B¹, de Lacey S¹, Smith C², Ratcliffe J³, ¹Flinders University, Adelaide, Australia, ²Western Sydney University, Sydney, Australia, ³University of South Australia, Adelaide, Australia

8:45-13:30 **RESEARCH POSTERS - SESSION III Hall 4**

9:45-10:15 **BREAK, EXHIBITS & RESEARCH POSTERS - SESSION III Hall 4**

Coffee Break Sponsored by Covance

COVANCE MARKET ACCESS
Experience Forward Thinking



10:15-12:00 **WELCOME & SECOND PLENARY SESSION Clyde Auditorium (Armadillo)**

WELCOME FROM ISPOR PRESIDENT

Shelby D. Reed, RPh, PhD, Duke University, Durham, NC, USA

WELCOME FROM ISPOR CHIEF SCIENCE OFFICER

Richard J. Willke, PhD, International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ, USA

2017 ISPOR AWARD FOR EXCELLENCE IN METHODOLOGY IN PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH

AWARDEE: Claire Rothery, PhD, University of York, Heslington, York, UK

2017 VALUE IN HEALTH REGIONAL ISSUES (CEEWA) EXCELLENT ARTICLE AWARD

AWARDEE: Aleš Tichopád, PhD, Kantar Health s.r.o., Prague, Czech Republic

SECOND PLENARY SESSION: Appraising the Appraisers: What is the Future of Health Technology Assessment in Europe?

Moderator: Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK

Speakers: Susan Guthrie, PhD, MSci, Rand Europe, Cambridge, UK; **Nicola Allen, PhD**, Precision for Value, London, UK; **Zoe Garrett, MPhil, MRes**, National Institute for Health and Care Excellence (NICE) and EUnetHTA, Manchester, UK

12:00-14:00 **LUNCH, EXHIBITS & RESEARCH POSTERS - SESSION III Hall 4**

Lunch Sponsored by BaseCase Management GmbH



12:30-13:30 **ISPOR MEDICAL DEVICES AND DIAGNOSTICS SPECIAL INTEREST GROUP OPEN MEETING Lomond Auditorium (Loch Suite)**

12:30-13:30 **ISPOR PATIENT CENTERED SPECIAL INTEREST GROUP OPEN MEETING Hall 1**

12:30-13:30 **EDUCATIONAL SYMPOSIUM Clyde Auditorium (Armadillo)**

Practical Implications of Value-Based Pricing and Emerging Value Frameworks in Health Technology Assessment

Moderator: Jay Jackson, PharmD, MPH, Xcenda, Palm Harbor, FL, USA

Speakers: Andrew Briggs, DPhil, MSc, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; **Ansgar Hebborn, PhD**, F.Hoffmann-La-Roche AG, Basel, Switzerland; **Ken O'Day, PhD, MPA**, Xcenda, Palm Harbor, FL, USA

(Sponsored by Xcenda)



12:30-13:30 **POSTER AUTHOR DISCUSSION HOUR - SESSION III Hall 4**



12:30-14:00 **ISPOR WOMEN IN HEOR/SCIENCE OPEN MEETING *Boisdale (Loch Suite)***

ISPOR is exploring the foundation of a “Women in HEOR/Science” initiative to help support the growth, development, and contribution of women in health economics and outcomes research (HEOR) and to serve as a catalyst for women’s leadership in the field. The objective of this session is to share the vision for the initiative and to gain feedback from members to help guide its development.

Speakers: 2017-2018 ISPOR President, **Shelby D. Reed, PhD, RPh**, Duke University, Durham, NC, USA; **Olivia Wu, PhD**, University of Glasgow, Glasgow, UK

14:00-15:00 **BREAKOUT SESSION**

IP11: Determining Value in Health Technology Assessment Consistent with Societal Aims: Pursue New Options? *Hall 2*

Moderator: **J. Jaime Caro, MDCM, FRCPC, FACP**, McGill University, Montreal, QC, Canada

Panelists: **Alistair McGuire, MLitt, PhD**, London School of Economics and Political Science, London, UK; **John Brazier, PhD, MSc**, University of Sheffield, Sheffield, UK; **Michael Schlander, MD, PhD, MBA**, Institute for Innovation & Valuation in Health Care (InnoVal-HC), Wiesbaden, Germany

IP12: What Should Patient-Centered Care Mean in the Welfare States of Europe? The United Kingdom and Germany Cannot Both Be Right *Hall 3*

Moderator: **F. Reed Johnson, PhD**, Duke Clinical Research Institute, Durham, NC, USA

Panelists: **Axel C. Mühlbacher, PhD, MBA**, Hochschule Neubrandenburg, Neubrandenburg, Germany; **Nancy Devlin, PhD**, Office of Health Economics, London, UK

W11: Determining the Value of Long Term Outcomes Associated With Immuno-Oncology Therapies - Challenges and Approaches for OS Extrapolations *Clyde Auditorium (Armadillo)*

Discussion Leaders: **Yiduo Zhang, PhD**, AstraZeneca, Gaithersburg, MD, USA; **Pralay Mukhopadhyay, PhD**, AstraZeneca, Gaithersburg, MD, USA; **Andrew Briggs, DPhil, MSc**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; **Nicholas Latimer, MSc, PhD**, University of Sheffield, Sheffield, UK

W12: Getting to the Heart of the Matter: Real-World Evidence as an Indispensable Source for the Ongoing Assessment of Cardiovascular Treatments *Forth (Armadillo)*

Discussion Leaders: **Kathleen E. Hughes, MBA**, Avalere Health LLC, Washington, DC, USA; **Colin Berry, FRCP, PhD**, University of Glasgow, Glasgow, UK; **Pall Jonsson, PhD**, National Institute for Health and Care Excellence (NICE), Manchester, UK; **Martin Zagari, MD**, Amgen Inc, Thousand Oaks, CA, USA

P11: Cost Studies *Hall 1*

CS1 Observed Versus Estimated Acquisition Costs Associated With Medicines Recommended by the All Wales Medicines Strategy Group

14:00-14:15

Keeping S, Deslandes PN, Haines K, Routledge PA, All Wales Therapeutics and Toxicology Centre, Llandough, UK

CS2 Costs of Chemotherapy-induced Adverse Events in Head and Neck Cancer in France

14:15-14:30

Lafuma A¹, Cotte F², Le Tourneau C³, Emery C⁴, Gaudin A², Torretton E¹, Gourmelen J⁵, Ouared C², **Bonastre J⁶**, ¹Cemka-Eval, Bourg La Reine, France, ²Bristol-Myers Squibb, Rueil-Malmaison, France, ³Institut Curie, Paris, France, ⁴Cemka, Bourg La Reine, France, ⁵UMS 011 - Inserm - UVSQ, Villejuif, France, ⁶Gustave Roussy, Villejuif, France

CS3 Costs of Illness Progression for Different Multiple Sclerosis Phenotypes: A Population-Based Study in Sweden

14:30-14:45

Gyllensten H, Kavaliunas A, Hillert J, Alexanderson K, Tinghög P, Friberg E, Karolinska Institutet, Stockholm, Sweden

CS4 Real Life Cost of Treatment and Follow-up Glioblastoma Multiforme (GBM) Patients Treated at the Antwerp University Hospital (UZA), Belgium

14:45-15:00

Van den Eede N¹, De Paepe A¹, Specenier P², Strens D³, ¹University of Antwerp, Antwerpen, Belgium, ²Antwerp University Hospital, Edegem, Belgium, ³Realidad bvba, Grimbergen, Belgium

P12: Modeling Methods *Lomond Auditorium (Loch Suite)*

MO1 Calibration Approach Impact on Health and Cost-Effectiveness Outcomes in a Decision Analytic Framework

14:00-14:15

Moriña D, Díaz M, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain

MO2 How Ireland’s Colorectal Screening Programme Could Save More Lives, Save Money and Stay Within Existing Colonoscopy Capacity Limits: Evidence From the MISCAN Microsimulation Model

14:15-14:30

McFerran E¹, O’Mahony JF², ¹QUEEN’S UNIVERSITY BELFAST, BELFAST, UK, ²Trinity College Dublin, Dublin, Ireland

MO3 Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology

14:30-14:45

Majer IM¹, Castaigne J², Palmer S³, DeCosta L⁴, Campioni M¹, ¹Amgen (Europe) GmbH, Zug, Switzerland, ²Amgen Oncology, Cambridge, UK, ³University of York, Heslington, York, UK, ⁴Amgen Ltd., Uxbridge, UK

MO4 Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness and Cost-Effectiveness Analyses

14:45-15:00

Keeney E¹, Dawoud D², Dias S¹, ¹University of Bristol, Bristol, UK, ²National Guideline Centre, Royal College of Physicians, London, UK



15:00-15:30 **BREAK & EXHIBITS Hall 4**

15:30-16:30 **BREAKOUT SESSION**

IP13: MCDA Valuation and ICERs – Can They Align for Decision-Making Purposes? (Invited Issue Panel) Clyde Auditorium (Armadillo)

Moderator: Louis P. Garrison, PhD, University of Washington, Seattle, WA, USA

Panelists: Charles E. Phelps, PhD, University of Rochester, Gualala, CA, USA; Maarten Ijzerman, PhD, MSc, University of Twente, Enschede, The Netherlands; Nancy Devlin, PhD, Office of Health Economics, London, UK

IP14: Patient-Centered Decision Making: How Do You Generate Relevant Patient-Reported Outcomes Evidence for Chronic Disease Management and Market-Access Decision Making? Hall 3

Moderator: Finn Børlum Kristensen, MD, PhD, University of Southern Denmark, Hilleroed, Denmark

Panelists: Katharine Barnard, PhD CPsychol AFBPsS, Bournemouth University, Poole, UK; Simon O'Neill, REG.N., Diabetes UK, London, UK; Francois Meyer, PhD, Haute Autorité de Santé (HAS), Saint-Denis, France

W13: Why is Your Outcome Different from Mine? Discussing the Potential Impact of Design Choices in the Development of Discrete Event Simulation Models Lomond Auditorium (Loch Suite)

Discussion Leaders: Elisabeth Fenwick, PhD, MSc, ICON plc, Abingdon, UK; Hendrik Koffijberg, PhD, University of Twente, Enschede, The Netherlands; Beate Jahn, PhD, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria; Koen Degeling, MSc, University of Twente, Enschede, The Netherlands

W14: Impact of Patient Involvement in Health Technology Assessments: A Case Study Hall 2

Discussion Leaders: Matthew May, BS, EPF, Brussels, Belgium; Joan Jordan, Multiple Sclerosis Society of Ireland, Dublin, Ireland; Michael Barry, MB, FRCPI, PhD, National Centre for Pharmacoeconomics (NCPE), Dublin, Ireland; Orlaith Brennan, MBA, Irish Pharmaceutical Industry Association, Dublin, Ireland

P13: Methodological Studies in Cancer Hall 1

CN5 Progression-Free Survival As a Surrogate Endpoint for Overall Survival in Patients With Relapsed or Refractory Multiple Myeloma

15:30-15:45

Dimopoulos M¹, Sonneveld P², Nahi H³, Kumar S⁴, Hashim M⁵, Kulakova M⁵, Duran M⁵, Heeg B⁵, Lam A⁶, Dearden L⁶, ¹National and Kapodistrian University of Athens, Athens, Greece, ²Erasmus MC, Rotterdam, The Netherlands, ³Karolinska Institute, Stockholm, Sweden, ⁴Mayo Clinic, Rochester, MN, USA, ⁵Ingress Health, Rotterdam, The Netherlands, ⁶Janssen Global Services, LLC, Raritan, NJ, USA

CN6 Can Bayesian Methodology Predict Long-Term Effectiveness Rather Than Efficacy? An Application With Overall Survival in Two Oncology Indications

15:45-16:00

Soikkeli F¹, Hashim M¹, Mueller S², Groth A², Wilke T³, Heeg B¹, ¹Ingress Health, Rotterdam, The Netherlands, ²Ingress-Health HWM GmbH, Wismar, Germany, ³INGRESS-Health HWM GmbH, Wismar, Germany

CN7 Estimating Long-Term Survival in the Face of Immature Data: A Case Study of Nivolumab in Second Line Renal Cell Carcinoma

16:00-16:15

Klijn SL¹, Torkilseng EB², Tyas D³, Sowdani A³, Malcolm B³, Mudd A¹, Johannesen KM⁴, ¹Pharmerit International, Rotterdam, The Netherlands, ²Bristol-Myers Squibb, Lysaker, Norway, ³Bristol-Myers Squibb, Uxbridge, UK, ⁴Bristol-Myers Squibb AB, Stockholm, Sweden

CN8 Length of Trial Period and Fit of Standard Survival Extrapolation Distributions for Ipilimumab in Melanoma

16:15-16:30

Ouwens MJ, Dalevi D, Astrazeneca, Molndal, Sweden

P14: Systemic Disorders/Conditions Studies Forth (Armadillo)

SY1 Psoriasis Drugs in Europe - Market Access Decisions in Comparison Based on the Prism Access Database

15:30-15:45

Vollmer L¹, de Paz B², Droschel D¹, Walzer S¹, ¹MARs- Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, ²PRIORITIS Market Access, Paris, France

SY2 WITHDRAWN

SY3 How Will Payers Manage the Cost of New, Advanced Biologic and Oncologic Agents As Therapy Areas Become Crowded With Drugs With Similar Mechanisms of Action?

15:45-16:00

Paglia R, Del Carlo A, Schwartz J, Carter EA, Consulting at McCann Health, New York, NY, USA

SY4 Do EU5 Countries With Favourable Healthcare Expenditure and Reimbursement Indicators Have Better Patient-Reported Access to Treatments for Rare Diseases?

16:00-16:15

Allen G¹, **Hall A¹**, Hanman K², Le Fevre R¹, Griffiths A¹, ¹Costello Medical Consulting Ltd, Cambridge, UK, ²Costello Medical Consulting Ltd, London, UK

15:30-19:15 **RESEARCH POSTERS - SESSION IV Hall 4**



16:45-17:45 **BREAKOUT SESSION**

IP15: A Modest Proposal: Can We Ease the Burden of Myriad Measures with a Minimum Data Set That Actually Matters to Patients? Hall 1

Moderator: Roman Casciano, MS, ANALYTICA LASER, New York, NY, USA

Panelists: Sheela Upadhyaya, MSc, NICE - National Institute for Health and Care Excellence, London, UK; Charles D. Petrie, PhD, Pfizer, Inc., Groton, CT, USA; Bettina Ryll, MD, PhD, Melanoma Patient Network Europe and Uppsala University, Uppsala, Sweden

IP16: Managed Entry Schemes for Medical Devices: Great Opportunity or Major Challenge? Hall 3

Moderator: Michael Drummond, MCom, DPhil, University of York, Heslington, York, UK

Panelists: Aleksandra Torbica, PhD, Bocconi University, Milano, Italy; Richard Charter, MSc, Becton Dickinson, Allschwil, Switzerland; Denis Gizzi, BSc, Sheffield Hallam University, Oldham, UK

W15: Time for a Change? Alternative Approaches to Modelling in Cancer Value Assessments Clyde Auditorium (Armadillo)

Discussion Leaders: Meindert Boysen, PharmD, MSc, National Institute for Health and Care Excellence (NICE), London, UK; Robert Hettle, MMath, PAREXEL International, London, UK; Beth Woods, MSc, University of York, Heslington, York, UK; Marta Soares, MSc, University of York, Heslington, York, UK

W16: Understanding the Value and Feasibility of Engaging Patients in the Design of Clinical Trials and Clinical Outcome Assessment Measurement Strategies: Insights from Experiences in Oncology and Gout Lomond Auditorium (Loch Suite)

Discussion Leaders: Bryan Bennett, PhD, Adelphi Values Ltd, Bollington, Cheshire, UK; Sophi Tatlock, MA, Adelphi Values Ltd, Bollington, Cheshire, UK; Stephanie Manson, PhD, Novartis, East Hanover, NJ, USA; Katja Rudell, PhD, Queen Mary University of London, London, UK

P15: Health Technology Assessment Studies Hall 2

HT5 16:45-17:00 "Appraising The Appraisers": Do National Health Technology Assessment Agencies (NICE, GBA/IQWiG) Follow Their Official Evaluation Criteria?

Schaefer R¹, Schwarz O², Schlander M³, ¹German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg, Germany, ²University of Heilbronn, Wiesbaden, Germany, ³University of Heidelberg, Heidelberg, Germany

HT6 17:00-17:15 Assessment of Medicines for Very Rare Conditions: Review of a New Approach Within the Scottish Medicines Consortium

Jones J, Brown A, Lee A, MacDonald A, Healthcare Improvement Scotland, Glasgow, UK

HT7 17:15-17:30 What Do the Single Technology Appraisals of the Past Tell Us About Fast-Tracking the Most Cost-Effective New Technologies in the Future?

Boland A¹, Houten R¹, Carroll C², Kaltenthauer E², Dickson R¹, ¹University of Liverpool, Liverpool, UK, ²University of Sheffield, Sheffield, UK

HT8 17:30-17:45 The Use of Published Real-World Evidence in HTA: An Analysis of the Evidence Base of Company Submissions in 2016 NICE Appraisals

Van Lier H, de Boeck M, Edwards V, Hanekamp E, Hartog TE, Richmond G, van den Broek R, Excerpta Medica, Amsterdam, The Netherlands

P16: Infectious Disease Studies Forth (Armadillo)

IN1 16:45-17:00 Estimating the Public Economic Impact of Different Hepatitis C Healthcare Policies in the Netherlands

Connolly M¹, Kotsopoulos N², ¹University of Groningen, Groningen, The Netherlands, ²Global Market Access Solutions, Saint-Prex, Switzerland

IN2 17:00-17:15 Cost-Effectiveness and Modeling Approaches of Direct-Acting Antiviral Agents in Chronic Hepatitis C Infection: A Systematic Literature Review

Szilberhorn L¹, Ágh T², Fasseeh AN¹, Kaló Z¹, ¹Eötvös Loránd University (ELTE), Budapest, Hungary, ²Syreon Research Institute, Budapest, Hungary

IN3 17:15-17:30 Differences in Vaccine Pricing Between High-Income and Low-Income Markets

Fadeyi I, McLean T, Tavella F, **Heron L**, Adelphi Values Ltd, Bollington, UK

IN4 17:30-17:45 Cost-Effectiveness of Additional Vaccination of Boys Against HPV in Germany

Damm O¹, Horn J², Ultsch B³, Scholz S¹, Mikolajczyk R², Wiese-Posselt M³, Harder T³, Wichmann O³, Greiner W¹, ¹School of Public Health, Bielefeld University, Bielefeld, Germany, ²Helmholtz Centre for Infection Research, Brunswick, Germany, ³Immunisation Unit, Robert Koch Institute, Berlin, Germany

17:45-19:15 **EXHIBITORS' WINE & CHEESE RECEPTION & RESEARCH POSTERS - SESSION IV Hall 4**

Reception Sponsored by Pharmedit International





18:00-19:00 **BREAKOUT SESSION**

F7: Health State Utility Identification and Use in Cost-Effectiveness in Decision Modelling *Clyde Auditorium (Armadillo)*

Moderator: John Brazier, PhD, MSc, University of Sheffield, Sheffield, UK

Speakers: Helene Chevrou-Severac, PhD, Celgene International, Boudry, Switzerland; Roberta Ara, MSc, The University of Sheffield, Sheffield, UK; Andrew Lloyd, DPhil, Acaster Lloyd Consulting Ltd., Oxford, UK

Presented by ISPOR Health State Utility Good Practices Task Force

F8: Innovation and Market Access in Asia-Pacific: What Evidence and Processes Are Appropriate for Reimbursement? China, Japan, South Korea, Taiwan and Australia Compared *Hall 3*

Moderator: Mendel Grobler, B.Pharm, MBA, Amgen Inc., North Ryde, NSW, Australia

Speakers: Shanlian Hu, MS, MD, Shanghai Health Development Research Center, Shanghai, China; Bruce Crawford, MPH, MA, InVentiv Health Japan G.K., Tokyo, Japan; Sukeyeong Kim, PhD, RPh, MPH, Coordinating Center for National Health Clinical Research, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South); Chee-Jen Chang, PhD, MS, Taiwan Society for Pharmacoeconomics and Outcome Research, Clinical Informatics and Medical Statistics Research Center, and Professor, Chang Gung University, Tao Yuan, Taiwan

Presented by ISPOR Asia Consortium Industry Committee

F9: Late Stage Oncology MCDA Criteria Implementation Results in European Countries *Hall 1*

Moderator: Vladimir Zah, PhD, ZRx Outcomes Research Inc., Belgrade, Serbia

Speakers: Oresta Piniashko, PhD, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine; Niki Popper, University of Technology Vienna, Vienna, Austria; Aleksandra Zawodnik, MSc Pharm, Medical University of Warsaw, Warsaw, Poland; Bertalan Nemeth, MSc, Syreon Research Institute, Budapest, Hungary

Presented by the ISPOR CEE Consortium and ISPOR Austria Chapter

F10: The Burden of COPD in Central & Eastern Europe *Forth (Armadillo)*

Moderator: Maria Kamusheva, PhD, Medical University of Sofia, Sofia, Bulgaria

Speakers: Josip Culig, MD, PhD, Andrija Stampar Institute of Public Health, Zagreb, Croatia; Konstantin Tachkov, PhD(c), Medical University of Sofia, Sofia, Bulgaria; Tamas Agh, MD, MSc, PhD, Syreon Research Institute, Hungary, Hungary; Mary Geitona, MD, University of Peloponnese, Korinthos, Greece

Presented by the ISPOR CEE Consortium

F11: The New Paradigm of Cancer Treatments: A Challenge for the Health Systems? *Lomond Auditorium (Loch Suite)*

Moderator: Carme Pinyol, MD, PhD, MSc, Pierre Fabre, Barcelona, Spain

Speakers: César Hernández, PhD, Spanish Agency of Medicines and Health Products, Barcelona, Spain; Jorge Mestre-Ferrandiz, PhD, OHE Collaborator, Madrid, Spain

Presented by ISPOR Spain Chapter

F12: Implementing Adaptive Pathways in Europe: A Central and Eastern Europe (CEE) Focus *Hall 2*

Speakers: André Broekmans, MD, PhD, Lygature and ADAPT SMART, Utrecht, The Netherlands; Zoltán Kaló, PhD, Eötvös Loránd University (ELTE) and Syreon Research Institute, Budapest, Hungary; Tomas Tesar, PharmD, PhD, MBA, MPH, Msc, Slovak Ministry of Health, Union Health Insurance Fund, Bratislava, Slovak Republic; Dominik Tomek, PharmD, MPH, PhD, MSc, European Patients Forum and Association for Patients' Right Protection in Slovakia, Bratislava, Slovakia

18:15-19:15 **POSTER AUTHOR DISCUSSION HOUR - SESSION IV *Hall 4***

19:30-23:30 **ISPOR SOCIAL EVENT (Separate Registration Required) *Merchant Square***

Join us for whisky tasting, dinner, and traditional dancing and music.

The event takes place at Merchant Square, once part of the old Glasgow Fruit Market, in the heart of Glasgow.

Guests will enjoy Scottish appetizers, whisky tasting, and have a choice of dinner options at the 5 restaurants within Merchant Square. A demonstration of Ceilidh dancing will be given and all will have the opportunity to participate in this easy-to-learn traditional dancing.

Separate registration required. The price is €90 and includes transportation from the SEC to Merchant Square and back to the SEC, buffet dinner, 2 drinks, and entertainment. Registration subject to availability, see the ISPOR Registration desk for details.

- If you have pre-registered for the Social Event, your ticket will print out with your name badge. You will need this ticket for entry to the bus/event.
- Buses will depart from the SEC between 19:30 and 20:00 for the 15-minute journey to Merchant Square.
- Return buses will start at 21:00, last bus at 23:15.





WEDNESDAY, 8 NOVEMBER

7:30-8:30 **EDUCATIONAL SYMPOSIUM *Lomond Auditorium (Loch Suite)***

Universal Value, The Way Forward?

Speakers: **Michael Blackney, PhD**, Covance Market Access, London, UK; **Ruth Zeidman, PhD**, Covance Market Access, London, UK; **Emanuela Castelnuovo, MSc**, Covance Market Access, London, UK; **Michael F. Drummond, MCom, DPhil**, University of York, Heslington, York, UK; **Don Redding, BA**, National Voices, London, UK

(Sponsored by Covance)

COVANCE MARKET ACCESS
Experience Forward Thinking



8:00-16:00 **REGISTRATION HELP DESK HOURS *Hall 5***

8:00-15:30 **SPEAKER READY ROOM HOURS *Fyne (Loch Suite)***

8:30-14:15 **EXHIBIT/POSTER HALL HOURS *Hall 4***

8:45-14:00 **RESEARCH POSTERS - SESSION V *Hall 4***

8:45-9:45 **BREAKOUT SESSION**

IP17: Deriving Utility Measures from Disease-Specific Quality of Life Instruments: Does Mapping to Generic Utility Instruments Adequately Capture the Patient Perspective in Economic Evaluation? *Hall 3*

Moderator: **Samuel Aballéa, PhD**, Creativ-Ceutical, Paris, France

Panelists: **Linda Abetz-Webb, MA**, Patient-Centred Outcomes Assessments, Bollington, UK; **Keith Tolley**, Tolley Health Economics Ltd., Buxton, UK; **Clément François, PhD**, Lundbeck, Deerfield, IL, USA

IP18: How Will Health Care Systems Handle Future Oncology Combination Product Launches? *Hall 2*

Moderator: **Bettina Ryll, MD, PhD**, Melanoma Patient Network Europe and Uppsala University (Department EBC), Uppsala, Sweden

Panelists: **Martina Weiss-Radtke, MBA**, Helsana Versicherungen AG, Zurich, Switzerland; **Jens Grueger, PhD**, F. Hoffmann-LaRoche, Division Pharma, Basel, Switzerland; **Meindert Boysen, PharmD, MSc**, National Institute for Health and Care Excellence, Manchester, UK

IP19: Can the Patient Voice Be Better Incorporated Into the NICE Process? *Lomond Auditorium (Loch Suite)*

Moderator: **Eric Low, NA**, East Lothian, UK

Panelists: **Jennifer Lee, MBA**, Janssen UK, High Wycombe, UK; **Heidi Livingstone, BA**, NICE, London, UK; **Richard Jackson, PGCE, NPQH**, Patient Expert, Cheshire, UK

W17: Comparing, Contrasting, and Validating Health Economic Decision Models: Experiences From the Latest Mt. Hood Challenge in Diabetes and Lessons for Other Disease Areas *Hall 1*

Discussion Leaders: **Alan Brennan, PhD**, University of Sheffield, Sheffield, UK; **Mark Lamotte, MD**, IQVIA, Zaventem, Belgium;

Talitha Feenstra, PhD, RIVM /UMCG, Bilthoven, The Netherlands; **Michael Willis, PhD**, The Swedish Institute for Health Economics, Lund, Sweden

W18: From One to Many: When Groups – Not Czars – Make Decisions *Forth (Armadillo)*

Discussion Leaders: **Charles E. Phelps, PhD**, University of Rochester, Gualala, CA, USA; **Guruprasad Madhavan, PhD**, National Academies of Science, Engineering, and Medicine, Washington, DC, USA

9:45-10:00 **BREAK, EXHIBITS & RESEARCH POSTERS - SESSION V *Hall 4***

10:00-11:00 **BREAKOUT SESSION**

IP20: Should ICER Be NICE (or Not)? How ICER's New Cost-Effectiveness Framework Compares with NICE's Guidelines *Hall 3*

Moderator: **Matthew Sussman, MA**, Boston Health Economics, Waltham, MA, USA

Panelists: **Dan Ollendorf, PhD**, Institute for Clinical and Economic Review, Boston, MA, USA; **Pall Jonsson, PhD**, National Institute for Health and Care Excellence (NICE), Manchester, UK

IP21: Adaptive Pathways for Transformative Medicinal Products: A New Paradigm with the Enhanced Application of Real-World Evidence? *Hall 2*

Moderator: **David Schwicker, MA**, ORPHA Strategy Consulting, Basel, Switzerland

Panelists: **Nicola Bedlington**, The Patient Access Partnership PACT, Brussels, Belgium; **Ad Schuurman, MA**, National Health Care Institute (ZIN), AH, The Netherlands; **Rob Thwaites, MA, MCom**, Takeda, London, UK



IP22: How Can We Assess the Value of New Antibiotics? *Lomond Auditorium (Loch Suite)*

Moderator: Chris Henshall, PhD, Office of Health Economics, London, UK

Panelists: Alec Morton, PhD, University of Strathclyde, Glasgow, Scotland, UK; Douglas Lundin, PhD, TLV, Stockholm, Sweden; Adrian Towse, MA, MPhil, Office of Health Economics, London, UK

W19: Generating Evidence to Support Off-Label Higher Value Cancer Treatment Regimens *Hall 1*

Discussion Leaders: Mark Sculpher, PhD, University of York, York, UK; Mark J. Ratain, MD, FASCO, The University of Chicago, Chicago, IL, USA; Peter Clark, MA, MD, FRCP, The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK; Virginia Acha, PhD, MSD Ltd., Hertfordshire, UK

W20: Disconnected or Limited Evidence in Network Meta-Analysis: What Can Be Done? *Forth (Armadillo)*

Discussion Leaders: Howard Thom, MSc, PhD, University of Bristol, Bristol, UK; Joy Leahy, BSc, Trinity College Dublin, Dublin, Ireland; Jeroen P. Jansen, PhD, MSc, Precision Health Economics, Vancouver, BC, Canada

11:15-12:45 WELCOME & THIRD PLENARY SESSION *Clyde Auditorium (Armadillo)*

WELCOME FROM ISPOR PRESIDENT, PRESENTATION OF ISPOR DISTINGUISHED SERVICE AWARDS, AND ANNOUNCEMENT OF ISPOR 21ST ANNUAL EUROPEAN CONGRESS

Shelby D. Reed, RPh, PhD, Duke University, Durham, NC, USA

AWARDEES:

Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK

Maarten IJzerman, PhD, University of Twente, Enschede, The Netherlands

THIRD PLENARY SESSION: Evolution of Value: Perspectives From Both Sides of the Atlantic

Moderator: Shelby D. Reed, PhD, RPh, Duke University, Durham, NC, USA

Speakers: Mandy Ryan, PhD, MSc, University of Aberdeen, Aberdeen, UK; Charles E. Phelps, PhD, University of Rochester, Gualala, CA, USA; Jérôme Wittwer, PhD, Bordeaux University, Bordeaux, France

12:45-14:15 LUNCH, EXHIBITS & RESEARCH POSTERS - SESSION V *Hall 4*

13:00-14:00 EDUCATIONAL SYMPOSIUM *Lomond Auditorium (Loch Suite)*

Does Accelerated Approval Deliver Accelerated Access? Experiences, Challenges, and Priorities

Moderator: Victoria Tzouma, MSc, London School of Economics and Political Science, London, UK

Speakers: Panos Kanavos, PhD, London School of Economics and Political Science, London, UK; Chris Hoyle, PhD, AstraZeneca, Cambridge, UK

(Sponsored by AstraZeneca)



13:00-14:00 POSTER AUTHOR DISCUSSION HOUR - SESSION V *Hall 4*

14:15-15:15 BREAKOUT SESSION

IP23: How Do You Incorporate the Patient Perspective into Health Technology Assessments? Defining Best Practices for Rigorous Scientific Evidence and Impactful Submissions and Reviews *Hall 3*

Moderator: Judith Leah Rubinstein, MIA, Context Matters Inc., New York, NY, USA

Panelists: Paola Kruger, MA, Accademia dei Pazienti/EUPATI Italia, Rome, Italy; Ken Bond, MA, CADTH, Ottawa, ON, Canada; Laure Delbecq, PhD, Pharmerit International, Rotterdam, The Netherlands

IP24: Trusting the Results of Model-Based Economic Analyses: Is There a Pragmatic Validation Solution? *Hall 2*

Moderator: J. Jaime Caro, MD, FRCPC, FACP, McGill University, Montreal, QC, Canada

Panelists: Matt Stevenson, PhD, University of Sheffield, Sheffield, UK; Jorgen Moller, MSc, Mech Eng, Evidera, Hammersmith, UK; Salah Ghabri, PhD, Haute Autorité de Santé, Saint-Denis La Plaine, France

IP25: Innovative Clinical Trial Designs: Welcomed by Regulators But What About the Payers? *Forth (Armadillo)*

Moderator: Richard Macaulay, PhD, PAREXEL International, London, UK

Panelists: Leanne Larson, MHA, PAREXEL International, Waltham, MA, USA; Andrew Walker, PhD, Salus Alba Consulting, Glasgow, UK; Detlev Parow, MD, MBA, D A K - Gesundheit, Hamburg, Germany

W21: Comparing Treatments by Combining Data from Various Randomized and Observational Studies: Introduction to Concept, Methods, and Application *Hall 1*

Discussion Leaders: Viktor Chirikov, PhD, Pharmerit International, Bethesda, MD, USA; Susanne Schmitz, PhD, Luxembourg Institute of Health, Strassen, Luxembourg; Farhan Mughal, MRPharmS, MSc, Celgene Ltd, Uxbridge, UK

W22: Negotiating Price and Data in an Era of Conditional Approval: "Stick" or "Twist"? *Lomond Auditorium (Loch Suite)*

Discussion Leaders: Daniel Gladwell, MSc, BresMed Health Solutions LTD, Sheffield, UK; Warren Cowell, MSc, Janssen Inc., High Wycombe, UK; Mark Strong, PhD, University of Sheffield, Sheffield, UK; Ash Bullement, BSc, BresMed Health Solutions, Sheffield, UK



15:15-15:30 **BREAK Concourse**

15:30-16:30 **BREAKOUT SESSION**

IP26: mHealth Among Clinicians and Patients in Cancer Care: How to Address the Digital Divide? Forth (Armadillo)

Moderator: Rosanna Tarricone, PhD, Bocconi University, Milan, Italy

Panelists: Maria Cucciniello, PhD, Bocconi University, Milan, Italy; Roma Maguire, PhD, MSc, University of Surrey, Glasgow, UK; Nicola Scalzo, MSc, European Commission, Brussels, Belgium

IP27: Valuing Children's HRQoL for Health Technology Assessment: What Are the Issues and Challenges? Hall 2

Moderator: Nancy Devlin, PhD, Office of Health Economics, London, UK

Panelists: Oliver Rivero-Arias, PhD, MSc, University of Oxford, Oxford, UK; Donna Rowen, PhD, University of Sheffield, Sheffield, UK; Deborah Morrison, MSc, NICE, Manchester, UK

IP28: Patient Preferences in European Drug Regulation – Are We Ready? Hall 1

Moderator: Douwe Postmus, PhD, University Medical Center Groningen, Groningen, The Netherlands

Panelists: Francesco Pignatti, MD, European Medicines Agency, London, UK; Pierre Demolis, MD, PhD, Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), Saint-Denis, France; Tommi Tervonen, PhD, Evidera, London, UK


W23: Improving Performance of Algorithms to Power Unmet Need and Effectiveness in Health Economics and Outcomes Research Using Electronic Health Records and Health Care Claims Data Sources Lomond Auditorium (Loch Suite)

Discussion Leaders: Hoa Van Le, MD, PhD, PAREXEL International, Durham, NC, USA; Aaron WC Kamaau, MD, MS, MPH, Anolinx LLC, Salt Lake City, UT, USA; Schiffon L Wong, MPH, EMD Serono, Inc., Billerica, MA, USA

W24: Population-Adjusted Treatment Comparisons in Health Technology Assessment: An Overview of Approaches and Perspectives Hall 3

Discussion Leaders: David M. Phillipppo, MSc, University of Bristol, Bristol, UK; Ahmed ElSada, MSc, National Institute for Health and Clinical Excellence, Manchester, UK; Mark Belger, BSc, Eli Lilly and Company, Surrey, UK; Nicky J. Welton, PhD, MSc, University of Bristol, Bristol, UK

< advertisement >



For more than 230 years, we have been serving society with innovative medicines and helping patients reclaim valuable moments of life from illness. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest.

We continue to transform the future of healthcare by unifying our strengths around the world. We are a diverse organization committed to working with local communities to fully understand their needs and deliver industry-leading solutions with a sense of urgency, dedication and unparalleled efficiency.

Our passion for healthcare and commitment to improving lives will enable us to make the next 230 years healthier and brighter for people around the world.

©2017 Takeda Pharmaceutical Company Limited. All rights reserved.

Mark your Calendars!

UPCOMING ISPOR EVENTS

23RD ANNUAL INTERNATIONAL MEETING

May 19-23, 2018

Baltimore, MD, USA

Abstract Submission Deadline: January 17, 2018

Early Registration Deadline: April 10, 2018

8TH ASIA-PACIFIC CONFERENCE

8-11 September 2018

Tokyo, Japan

Abstract Submission Opens: 1 November 2017

Abstract Submission Deadline: 14 March 2018

Early Registration Deadline: 17 July 2018

21ST ANNUAL EUROPEAN CONGRESS

10-14 November 2018

Barcelona, Spain

Abstract Submission Opens: 1 March 2018

Abstract Submission Deadline: 13 June 2018

Early Registration Deadline: 25 September 2018

WING TECH INC.

Independent analytical expertise
to help **innovators**
discover, validate, and articulate
the **value** of medical technologies



Tuesday, November 7

8:45 am – 1:30 pm

Changes in Acute Medication Cost Observed in Cluster Headache Patients Treated with Sphenopalatine Ganglion (SPG) Stimulation: A UK NHS-Specific Analysis Based on Data from the Pathway R1 Registry

(Research Posters III, abstract PMD34)

Clinical and Economic Benefit of Upper Airway Stimulation for Obstructive Sleep Apnea in the German Setting

(Research Posters III, abstract PMD51)

wing-tech.com • consulting@wing-tech.com • +1-650-943-3000

Menlo Park, CA • Irvine, CA • Potomac, MD • Karlsruhe, Germany

**Better
Analysis
for
Better
Decisions**

Visit us at the 2017 ISPOR European Congress, booth 113



Invitational Group Meetings

The following is a list of the by invitation only ISPOR group meetings during ISPOR Glasgow. ISPOR members worldwide are actively participating in ISPOR working groups to advance global health outcomes research and the use of this research in health care decisions.

These ISPOR groups provide an opportunity for members to contribute to translating outcomes research to health care decisions.

Please note: invitees will receive an email reminder and notification of any changes to this ISPOR group meeting schedule

SUNDAY, 5 NOVEMBER

Lunch on your own for short course delegates

8:30-15:00	ISPOR HTA Roundtable - Europe	<i>Gallery Bistro (upstairs off the Mezzanine)</i>
11:30-12:30	ISPOR Publications Management Advisory Board and Journal Editors-in-Chief Joint Business Meeting	<i>Katrine (Seminar Suite)</i>
12:00-12:45	ISPOR HTA Roundtable - Europe Luncheon	<i>Gallery Bistro (upstairs off the Mezzanine)</i>
14:30-17:30	ISPOR Health Science Policy Council	<i>Morar-Ness (Seminar Suite)</i>
15:30-17:30	ISPOR HTA Roundtable - Middle East and Africa	<i>Gallery Bistro (upstairs off the Mezzanine)</i>
16:00-17:30	ISPOR Health Science Policy Council Breakout	<i>Katrine (Seminar Suite)</i>
17:45-18:45	ISPOR Africa Network Executive Committee	<i>Leven (Seminar Suite)</i>

MONDAY, 6 NOVEMBER

12:15-14:15 Lunch for delegates served in the Exhibit Poster Hall

7:15-8:15	ISPOR Value & Outcomes Spotlight Editorial Board	<i>Carron (Loch Suite)</i>
7:30-8:30	ISPOR Statistical Methods in Health Economics and Outcomes Research Special Interest Group	<i>Morar-Ness (Seminar Suite)</i>
7:30-8:30	ISPOR Asia Consortium Business Meeting	<i>Alsh (Loch Suite)</i>
12:00-13:45	ISPOR Health State Utility Estimates in CE Models Task Force	<i>Katrine (Seminar Suite)</i>
12:00-14:00	ISPOR Institutional Council Lunch	<i>Leven (Seminar Suite)</i>
12:15-14:00	ISPOR Value in Health Editorial Board and Editorial Advisory Board	<i>Morar-Ness (Seminar Suite)</i>
12:30-13:45	ISPOR CEE Consortium Working Committees: Research, Education, Publication	<i>Dochart (Loch Suite)</i>
12:30-17:00	ISPOR Patient Representatives Roundtable	<i>Gallery Bistro (upstairs off the Mezzanine)</i>
13:45-15:15	ISPOR Expert Elicitation Task Force	<i>Katrine (Seminar Suite)</i>
14:00-15:00	ISPOR Arabic Network Executive Committee	<i>Carron (Loch Suite)</i>
14:15-15:15	ISPOR Poland Chapter	<i>Morar-Ness (Seminar Suite)</i>
15:00-16:00	ISPOR Global Engagement Council	<i>Leven (Seminar Suite)</i>
14:30-16:00	ISPOR Chapters of the Eurasian Economic Union Countries Joint Meeting	<i>Dochart (Loch Suite)</i>
14:30-16:00	ISPOR Greece Chapter	<i>Boisdale (Loch Suite)</i>
15:15-16:45	ISPOR Proposed Stated Preference Methods in Decision Making Good Practices Task Force	<i>Katrine (Seminar Suite)</i>
16:30-17:30	ISPOR Hungary Chapter	<i>Boisdale (Loch Suite)</i>
16:30-17:30	ISPOR Past President's Council	<i>Leven (Seminar Suite)</i>
17:00-18:00	ISPOR Portugal Chapter	<i>Morar-Ness (Seminar Suite)</i>



Invitational Group Meetings

TUESDAY, 7 NOVEMBER

12:00-14:00 Lunch for delegates served in the Exhibit Poster Hall

7:30-10:00	ISPOR HTA Council	<i>Ness (Seminar Suite)</i>
7:45-8:45	ISPOR Patient-Centered Special Interest Group	<i>Katrine (Seminar Suite)</i>
8:45-9:45	ISPOR Austria Chapter	<i>Alsh (Loch Suite)</i>
8:45-9:45	ISPOR Italy-Rome Chapter	<i>Dochart (Loch Suite)</i>
12:00-13:45	ISPOR Optimization Task Force	<i>Katrine (Seminar Suite)</i>
12:00-14:00	ISPOR Student Network/Faculty Advisor Luncheon	<i>Carron (Loch Suite)</i>
12:30-13:30	ISPOR HTA Council Working Group - HTA Scoping Paper	<i>Ness (Seminar Suite)</i>
12:30-14:30	ISPOR CEE Consortium Executive Committee	<i>Dochart (Loch Suite)</i>
13:45-15:15	ISPOR Value of Information Task Force	<i>Katrine (Seminar Suite)</i>
14:00-18:00	ISPOR Educational Forum: "Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as Evidence-Based Health Technology Assessment (HTA) specifically for Off-Patent Pharmaceuticals in Emerging Markets" (supported by an educational grant from Abbott)	<i>Gallery Bistro (upstairs off the Mezzanine)</i>
14:45-15:45	ISPOR ViHRI CEEWAA Editorial Board & Editorial Advisory Board	<i>Ness (Seminar Suite)</i>
15:00-16:00	ISPOR Ukraine and Serbia Chapters	<i>Alsh (Loch Suite)</i>
15:15-16:45	ISPOR Stated Preference Research in EU Working Group	<i>Katrine (Seminar Suite)</i>
16:15-17:15	ISPOR Spain Chapter	<i>Alsh (Loch Suite)</i>
16:30-17:45	ISPOR Europe Chapters Presidents and EUPATI	<i>Dochart (Loch Suite)</i>
19:15-20:00	ISPOR Bulgaria Chapter	<i>Carron (Loch Suite)</i>

WEDNESDAY, 8 NOVEMBER

12:45-13:45 Lunch for delegates served in the Exhibit Poster Hall

9:00-10:30	ISPOR Russia HTA Chapter	<i>Dochart (Loch Suite)</i>
------------	--------------------------	-----------------------------



ISPOR Congress App


Your meeting.
Your way.
In *your* pocket.

**A simple, yet powerful, tool
to get the most out of your
ISPOR congress experience.**



Search: ISPOR

**WI-FI NETWORK: ISPORGLASGOW
PASSWORD: IQVIA2017**



Released Presentations

Looking for presentations from ISPOR Glasgow?

**www.ispor.org » 20th Annual European Congress »
Released Presentations**

Presentations are available online after each session, subject to speaker approval.

**Over 85% of presentations are
expected to be available!**



Research Poster Presentations Overview

Nearly 2200 poster presentations will be on display during the congress in the Poster and Exhibit Hall (Hall 4).

- The poster hall is organized in rows (A-N) and each poster board is numbered accordingly (e.g. A1, L15)
- Each poster presentation has been assigned a specific numbered board location, which is shown next to the poster presentation title. Please note that this is different than the poster code (e.g. PHP1, PCV5), which was assigned to each poster presentation upon acceptance.
- Poster presentation titles and authors, as well as the numbered board location, are available on the myISPORGlasgow.zerista.com web platform and mobile app. This information is also available as a PDF on the ISPOR website.
- An Author index is available in Value in Health 20 (9), which is available near ISPOR registration and online at http://www.ispor.org/valueinhealth_index.asp.
- Poster board numbering is available on the floor plan on page 37 and row locations (by topic) are available in the table below.

POSTER PRESENTATION SESSIONS	POSTER LOCATION	PRESENTER SET UP TIME	POSTER DISPLAY HOURS	AUTHOR DISCUSSION HOUR*	PRESENTER DISMANTLE TIME**
SESSION I: MONDAY, 6 NOVEMBER					
PCN: CANCER	ROWS A-L	8:30-8:45	8:45-13:45	12:45-13:45	13:45
PDB: DIABETES/ENDOCRINE DISORDERS	ROWS L-N				
PUK: URINARY/KIDNEY DISORDERS	ROWS N				
SESSION II: MONDAY, 6 NOVEMBER					
PHS: HEALTH SERVICES	ROWS A-F	15:30-15:45	15:45-19:30	18:30-19:30	19:30
PIH: INDIVIDUAL'S HEALTH	ROWS F-G				
PMS: MUSCULAR-SKELETAL DISORDERS	ROWS G-J				
PSY: SYSTEMIC DISORDERS/CONDITIONS	ROWS J-N				
SESSION III: TUESDAY, 7 NOVEMBER					
PMD: MEDICAL DEVICES/DIAGNOSTICS	ROWS A-F	8:30-8:45	8:45-13:30	12:30-13:30	13:30
PCV: CARDIOVASCULAR DISORDERS	ROWS F-K				
PGI: GASTROINTESTINAL DISORDERS	ROWS K-L				
PRS: RESPIRATORY-RELATED DISORDERS	ROWS L-N				
SESSION IV: TUESDAY, 7 NOVEMBER					
PHP: HEALTH CARE USE & POLICY STUDIES	ROWS A-K	15:15-15:30	15:30-19:15	18:15-19:15	19:15
PMH: MENTAL HEALTH	ROWS K-L				
PND: NEUROLOGICAL DISORDERS	ROWS L-N				
SESSION V: WEDNESDAY, 8 NOVEMBER					
PRM: RESEARCH ON METHODS	ROWS A-I	8:30-8:45	8:45-14:00	13:00-14:00	14:00
PIN: INFECTION	ROWS I-M				
PSS: SENSORY SYSTEMS DISORDERS	ROWS M-N				

*Presenters are required to be with their posters during the Poster Author Discussion Hour.

**Posters that are not removed at the scheduled dismantle times will be discarded.



Exhibit Program Overview

Exhibits Viewing

Exhibits will be on view in Hall 4.

Monday, 6 November: 8:30-19:45

Tuesday, 7 November: 8:30-19:15

Wednesday, 8 November: 8:30-14:15



Networking Lounges, Charging Stations, and Internet Stations

Please enjoy the various lounges, charging stations, and internet stations on the Exhibit floor.

New this year!

Business Café *Sponsored by Complete HEOR Solutions (CHEORS)*

Networking/Charging Lounge *Sponsored by IQVIA*

Internet stations are available in the front of Hall 4 at the Poster/Exhibit Look-Up Station.

Internet Access/Wi-Fi *Sponsored by IQVIA*



Schedule

SUNDAY, 5 NOVEMBER

8:00-18:00 Exhibitor Set Up

MONDAY, 6 NOVEMBER

8:30-19:45 Exhibits Viewing

10:45-11:15 Coffee Break

12:15-14:15 Lunch *Sponsored by Health Economics and Outcomes Research Ltd*

15:15-15:45 Coffee Break *Sponsored by Ingress Health*

18:00-19:45 Exhibitors' Open House Reception *Sponsored by Complete HEOR Solutions (CHEORS)*



TUESDAY, 7 NOVEMBER

8:30-19:15 Exhibits Viewing

9:45-10:15 Coffee Break *Sponsored by Covance*

12:00-14:00 Lunch *Sponsored by BaseCase Management GmbH*

15:00-15:30 Coffee Break

17:45-19:15 Exhibitors' Wine & Cheese Reception *Sponsored by Pharmerit International*

COVANCE MARKET ACCESS
Experience Forward Thinking



WEDNESDAY, 8 NOVEMBER

8:30-14:15 Exhibits Viewing

9:45-10:00 Coffee Break

12:45-14:15 Lunch

14:15 Exhibitor Dismantle



Congress Exhibitors


COMPANY NAME	EXHIBIT LOCATION	COMPANY NAME	EXHIBIT LOCATION	COMPANY NAME	EXHIBIT LOCATION
Accession	801	Gareth Lee (G&J Lee Recruitment)	Table #3	PHMR*	201
Adelphi	301	GfK	207	Pope Woodhead	306
Advanced Clinical Recruitment	202	HealthCore, Inc.*	215	PRA Health Sciences	307
Amaris	807	Health iQ	802	Precision Health Economics (Part of Precision for Value)*	702
AMICULUM	Table #1	HEVA Group	221	Prioritis Ltd	602
AMPLEXOR Life Sciences	109	HTA Consulting	309	PRMA Consulting	404
Analysis Group	123	ICON plc	503	ProClinical	805
ANALYTICA LASER	703	IGES Group	122	Quantify	210
AplusA	405	INC Research/inVentiv Health	605	Regulatory Pharma Net srl	114
AXIS Consulting	505	Ingress Health*	304	Remap Consulting	205
Barrington James	212	institute for Medical Technology Assessment (iMTA)	203	R-Squared Talent Solutions	107
BaseCase Management GmbH*	814	INTEXO SRL	220	RTI Health Solutions	402
BresMed	501	Ipsos Healthcare	120	RWS Life Sciences	310
Cardinal Health Specialty Solutions	811	IQVIA*	701	SchHARR, University of Sheffield	314
Cochrane Innovations	Table #8	ISPOR	401	SEC Recruitment	104
CEMKA	407	Journal of Health Economics and Outcomes Research	Table #4	SIRIUS Market Access*	305
Complete HEOR Solutions (CHEORS)*	812	Kantar Health	704	STATinMED Research	102
CONSULTING AT McCANN HEALTH	604	Lifescience Dynamics	311	stève consultants	208
Context Matters	313	Lightspeed Health	Table #9	Synergus	108
Costello Medical Consulting	316	MA Provider Srl	Table #5	Talentmark	Table #6
Covance*	317	MAESTrO Database	302	Taylor & Francis	219
CRA, Charles River Associates	507	MAP BioPharma	103	Tolley Health Economics Ltd.	121
Creativ-Ceutical	213	Market Access Transformation	112	TransPerfect	101
CRECON Medical Assessment Inc.	406	MINERVA Network	408	TreeAge Software	204
Crystallise Ltd	Table #2	Mtech Access	303	Truven Health Analytics, IBM Watson Health*	502
Curo	806	Navigant	506	University of Glasgow	106
Decision Resources Group	403	NEXTEP	115	Valid Insight	217
Digital Health Outcomes & GMAS	111	Numerus	218	ValueMAxess Ltd	312
Dolon Ltd	118	Open Health/pH Associates/OAC	105	Vitaccess	804
Dymaxium	116	Optum	211	Wickenstones	206
emedcareers	Table #10	Oxford PharmaGenesis	214	Wing Tech Inc.	113
EORTC	Table #7	OXON EPIDEMIOLOGY	810	Xcenda	603
Evidence Partners Inc.	119	PAREXEL International	308	York Health Economics Consortium	504
Evidencia Scientific	808	Patients Direct	110	ZRx Outcomes Research Inc.	809
Evidera*	601	Pharmatelligence	315		
Excerpta Medica	216	Pharmerit International*	813		
FACIT.org/FACITtrans	117	PHARMO Institute	803		
GalbraithWight	209				

* Exhibitors who are also sponsors



Exhibit/Poster Hall Floor Plan

Hall 4



Nearly 2200 poster presentations will be on display during the congress:

- SESSION I: MONDAY, 6 NOVEMBER from 8:45-13:45
- SESSION II: MONDAY, 6 NOVEMBER from 15:45-19:30
- SESSION III: TUESDAY, 7 NOVEMBER from 8:45-13:30
- SESSION IV: TUESDAY, 7 NOVEMBER from 15:30-19:15
- SESSION V: WEDNESDAY, 8 NOVEMBER from 8:45-14:00

Exhibits will be on view:

- Monday, 6 November from 8:30-19:45
- Tuesday, 7 November from 8:30-19:15
- Wednesday, 8 November from 8:30-14:15




PPI Healthcare Consulting

Adding global value through local expertise and insight

"Securing optimal market access for any medical technology, regardless of its novelty, is becoming increasingly difficult, requiring strategic planning and a thorough insight of stakeholders' practices and expectations. PPI HC has been providing its clients with such insight and guidance since 2001 and would welcome the opportunity to assist you."

Adam Barak, Managing Director

Completed Country Assignments up to 2017:



Pricing and Reimbursement (P&R) Consulting Services:

- Develop national/international pricing strategy throughout product planning process and post-launch
- Implementing and facilitating P&R submissions and revisions
- Direct stakeholder and secondary research to inform positioning and value demonstration strategies

Market Research Consulting Services:

- Market landscaping and segmentation
- Market access and payer research
- Product positioning, messaging
- Qualitative and quantitative research

Health Economic Consulting Services:

- Develop core and country-tailored value /submission dossiers
- Provide value and clinical evidence-generation needs including supportive studies design

For further information please contact PPI HC on:

Tel: +44 (0)2380 847891 Email: info@ppi.consulting Web: www.ppi.consulting



Key Information

WiFi and Internet Access

Internet stations are provided in the **Exhibit-Poster Hall located in Hall 4**.

For the convenience of Congress attendees, Wi-Fi is available in the convention center.

Network: ISPORGlasgow // Password: IQVIA2017

Wi-Fi is only intended for checking email and using the congress mobile app, not for downloading files. Connection speeds will vary depending on the volume of users.

Internet/Wi-Fi Sponsored by IQVIA

Registration Disclaimer

For security purposes all individuals must be registered and wear the official ISPOR Event Name Badge to gain access to the event, the sessions, the exhibit poster hall, and any other ISPOR activity. Onsite staff and security will monitor for name badges and will deny access if individual does not have an official ISPOR Event Name Badge. Individuals not wearing a name badge will be directed to registration. Please note that if you lose your name badge and need to have it re-printed you cannot print that at the self-serve station, you will need to visit the registration help desk.

Because of the professional nature of the program, safety and liability reasons; guests and anyone under the age of 18 are not permitted access or to register for the event. This includes access to the event in general, to scientific presentations, and to the exhibit and poster hall.

For any ISPOR sponsored social event, guests over the age of 21 are permitted to attend but must have a paid event ticket. Due to insurance and liability no one under 21 will be permitted to attend a social event.

Language Information

All sessions at the ISPOR 20th Annual European Congress are presented in English. ISPOR regrets that due to the disruption to other delegates, whisper translation (chuchotage) is not permitted in any session, including short courses. To discuss options to meet educational needs in multiple languages, please contact meetingsinfo@ispor.org.

Presentation Slides/Posters

Plenary session, issue panel, workshop, ISPOR forum, and symposia slides will be available via the congress app and at the ISPOR 20th Annual European Congress Released Presentations page at www.ispor.org during/after the congress, subject to speaker approval.

Podium and poster presentation abstracts and released slides or poster PDFs are available at the ISPOR Scientific Presentations Database (a searchable database of over 42,000 research papers presented at ISPOR meetings) at http://www.ispor.org/research_study_digest/index.asp.

The Released Presentations page will feature many of the congress' slide presentations as PDFs. In 2016, more than 80% of the presentations were available to the public during/after the congress. The Released Presentations page is accessible via the congress mobile app and at www.ispor.org » 20th Annual European Congress.

Speaker Information

Upload the final version of your slide presentation in the Speaker Ready Room on the same day of your session!

All speakers are encouraged to use the Speaker Ready Room to preview their slide presentation and/or upload an updated version. Presentations submitted to ISPOR Speaker's Corner by the specified advance deadline and all presentations uploaded/updated in the Speaker Ready Room **30 minutes** prior to the session will be pre-loaded to the computer in the session room. All speakers are requested to arrive at their presentation room 15 minutes prior to the session start time. ISPOR staff will be available in the session room to assist the presenter.

A **speaker ready room** is provided in **Fyne (Loch Suite)** with the opening hours:

- Sunday, 5 November: 12:00-18:00
- Monday, 6 November: 8:00-18:00
- Tuesday, 7 November: 8:00-18:00
- Wednesday, 8 November: 8:00-15:30

ISPOR Research Presentation Awards



Awards are given for the best research presentations for podiums and posters in the categories of GENERAL, NEW INVESTIGATOR, and STUDENT (up to 3 in each category).

All research podium presentations are considered for an award. The top 10% of research poster presentations, based on abstract review score, are considered for a poster presentation award. These are identified with a rosette and will be judged during the Congress.

Award recipients will be notified by email and recognized on the ISPOR website at the conclusion of the congress.

ISPOR Social Event: A Taste of Scotland

TUESDAY, 7 November 19:30-23:30

Merchant Square

Join us for whisky tasting, dinner, and traditional dancing and music.

The event takes place at Merchant Square, once part of the old Glasgow Fruit Market, in the heart of Glasgow.

Guests will enjoy Scottish appetizers, whisky tasting, and have a choice of dinner options at the 5 restaurants within Merchant Square. A demonstration of Ceilidh dancing will be given and all will have the opportunity to participate in this easy-to-learn traditional dancing.

Separate registration required. The price is €90 and includes transportation from the SEC to Merchant Square and back to the SEC, buffet dinner, 2 drinks, and entertainment. Registration subject to availability, see the ISPOR Registration desk for details.

- If you have pre-registered for the Social Event, your ticket will print out with your name badge. You will need this ticket for entry to the bus/event.
- Buses will depart from the SEC between 19:30 and 20:00 for the 15-minute journey to Merchant Square.
- Return buses will start at 21:00, last bus at 23:15.

Social Media

Communicating by way of social media is encouraged if it falls within embargo and communications rules.



Be part of the live discussion!

- Tweet your comments to @ISPORorg during the congress using #ISPORGlasgow
- Access expert insights and share your views on congress sessions at the ISPOR LinkedIn Discussion Group: <http://bit.ly/ISPOR-LIn>
- Network with your peers on the ISPOR Facebook page: <http://bit.ly/ISPOR-FB>

Recording and Press Information

ISPOR supports the promotion of research presented at ISPOR congresses, while safeguarding sensitive information, data, and research findings that are not yet available to the public. **Due to the sensitive nature of data and the particularly preliminary, unpublished research findings, all filming and recording of scientific sessions and the poster hall is prohibited during the congress, without the express written consent of ISPOR.**

Portions of the ISPOR 20th Annual European Congress may be recorded by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). By participating in the discussions, congress registrants agree that ISPOR may electronically copy, videotape, or audiotape their attendance at and involvement in any program. Registration and attendance at the ISPOR 20th Annual European Congress constitutes an agreement by the registrant to ISPOR's use and distribution (both now and in the future) of their image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities. ISPOR will strictly enforce its rights as the exclusive licensee of all publication and reproduction rights to each presentation, and no presentation, in whole or in part, may be reproduced without approval from ISPOR. Congress attendees must gain approval from a speaker or poster presenter prior to quoting or publishing that individual's scientific results. Members of the press must identify themselves as such before questioning speakers and congress attendees if using the information in a professional capacity. More detailed information on ISPOR's Press Pass, Legal, and Embargo Policies are available on ISPOR's News & Press page at the ISPOR website (www.ispor.org).

For further questions on these policies, please contact: Betsy Lane (blane@ispor.org), Director and Chief Marketing & Communications Officer.

Congress Program Disclaimer

Please be advised that while the congress program is designed to provide accurate information regarding the subject matter covered, the views, opinions, and recommendations expressed are those of the authors and speakers, not the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and thus ISPOR does not guarantee the accuracy of the information disseminated. If professional advice is desired, please consult a competent professional.

Antitrust Compliance

It is the undeviating policy of ISPOR to comply strictly with the letter and spirit of all local and U.S. Federal, State, and applicable international trade regulations and antitrust laws. Any activities of ISPOR or ISPOR-related actions of its officers, Executive Committee Members, or members that violate these regulations and laws are detrimental to the interests of ISPOR and are unequivocally contrary to ISPOR policy.

Financial Disclosure Information

Research podium and poster presentation financial disclosure information is available online at: http://www.ispor.org/valueinhealth_index.asp and in the October/November 2017 issue of *Value in Health*. Faculty and staff involved in the planning or presentation of this congress are required to disclose all real or apparent commercial financial affiliations related to congress content. This information is available on request at the ISPOR Registration desk.

Questions & Information

Please ask ISPOR staff members for any additional information about the congress or about ISPOR. ISPOR staff can be identified by their ISPOR name badge.

Conference Rooms Floor Plan

